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ABSTRACT 
 
Acute limb compartment syndrome (ACS) causes a unique form of limb 
ischaemia, which induces intense inflammatory response resulting in 
microcirculatory dysfunction, neutrophil activation and cell injury. Increased 
intracompartmental pressure is the hallmark of ACS. Decompression by 
fasciotomy is the gold standard treatment. While fasciotomy saves the limb from 
ischaemic threat, paradoxically, it causes further damage to the muscle by 
reperfusion injury. In addition, it does not address the inflammatory element 
purported to increase the tissue injury in ACS. 
Recent evidence suggests that hydrogen sulfide (H2S) can mitigate the 
damage associated with ischaemia-reperfusion injury. The purpose of this thesis 
was to examine the value of H2S treatment in a rat model of ACS, using 
GYY4137 as H2S-releasing molecule. We have demonstrated significant 
cytoprotective role of H2S on the skeletal muscle following ACS.  
These results suggest a potential therapeutic value of H2S as an 
adjunctive to fasciotomy, for patients suffering ACS. 
 
 
 
Keywords: acute compartment syndrome; fasciotomy; tissue injury; 
inflammation; hydrogen sulfide; carbon monoxide; GYY4137; 
CORM-3. 
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CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW 
 
1.1. COMPARTMENT SYNDROME 
1.1.1. Overview 
Acute compartment syndrome (ACS) is a unique form of ischemia 
affecting group of muscles and nerves enclosed within a relatively noncompliant 
fascial sheath (Matsen, Winquist, and Krugmire 1980; Sadasivan et al. 1997). 
The hallmark of ACS is elevation of the intracompartmental pressure (ICP), 
which results in progressive microvascular ischemia and, if left untreated, leads 
to muscle cell death, loss of motor function, or loss of limb (Matsen 1975; 
Rorabeck 1984). The severity of cellular deterioration observed in ACS appears 
to be more than that seen in ischemia alone (Heppenstall et al. 1988; 
Heppenstall et al. 1989). 
ACS is a critical clinical episode that typically occurs after trauma, and 
represents a diagnostic and therapeutic challenge to orthopaedic surgeons. 
Emergency surgical decompression by fasciotomy remains the only proven 
treatment that mitigates the high pressure, thus saving the tissues from 
progressive damage (Matsen, Winquist, and Krugmire 1980; Shaw and Spencer 
1995). However, fasciotomy is not an entirely benign procedure and is 
associated with substantial morbidity, as well as potential mortality (Shaw and 
Spencer 1995; McQueen and Court-Brown 1996). The awareness of ACS has 
increased significantly in the recent years due to serious complications that 
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resulted in medicolegal issues (Taylor, Sullivan, and Mehta 2012; Shadgan et al. 
2010; Giannoudis et al. 2002). 
Solid evidence suggests that intense inflammatory response and release 
of reactive oxygen metabolites are critically involved in the development of the 
cellular damage in ACS (Perler, Tohmeh, and Bulkley 1990; Sadasivan et al. 
1997; Kearns et al. 2004; McGarr 2009; Lawendy, Sanders, Bihari, and Badhwar 
2011; Lawendy 2014a). Despite the high morbidity and litigation associated with 
ACS, there is no medical treatment available for routine use, as an adjunctive to 
surgical decompression to improve the prognosis. Conversely, with the current 
available knowledge of the pathophysiology of ACS and ischaemia reperfusion 
injury, there could be a chance to discover a therapeutic agent that may improve 
the tissue tolerance to ischaemia, or reduce its deleterious effects. 
 
1.1.2. Sequelae Of ACS 
The outcome of untreated ACS is catastrophic. Ischaemic insult to the 
nerve and muscle may lead to muscle contractures, joint stiffness and 
neurological deficits, resulting in severe functional disabilities. Amputation may 
be necessary in some cases, particularly if opportunistic infection flares up in the 
dead muscles (Styf 2003). The deleterious effects of ACS do not occur only 
locally in the affected limb, but may also happen systemically, resulting in remote 
organ involvement and severe metabolic disturbance (Heemskerk and Kitslaar 
2003; Finkelstein, Hunter, and Hu 1996; Bocca et al. 2002; McQueen and 
Duckworth 2014; Whitesides and Heckman 1996; Malik et al. 2009). Acute renal 
3 
 
failure, and even death from the ‘crush syndrome’ are known results of massive 
muscle necrosis seen in ACS (Reis and Michaelson 1986). The complications 
are strongly related to the duration of ACS (Pearse 2002). Many researchers 
reported good clinical recovery if fasciotomy was performed within 6 hours 
(Rorabeck and Clarke 1978). However, irreversible damage has been reported in 
37% of patients after only 3 hours of ACS in a large clinical study (Vaillancourt et 
al. 2004). The 3-hour window was found to be comparable with a tourniquet-
induced ischemia in an animal experimental model (Heppenstall et al. 1986). It 
was reported that only 8% of patients regained useful function when surgery had 
been done after 12 hours of ACS (Sheridan and Matsen 1976). 
 
1.1.3. Historical Perspective 
Richard Volkmann was one of the first to realise that ACS resulted from an 
ischaemic insult to the muscles rather than just nerve paralysis, as it had been 
believed. He named the condition “ischaemic muscle paralysis and contracture” 
pointing to both, the known pathology and the common end result (Volkmann 
1881; Volkmann 2007). This term was then adopted by several authors 
(Huntington 1907; Hildebrand 1906; Düben 1969; Botte et al. 1996). In 1908, the 
term “Volkmann's ischemic paralysis and contracture” appeared in the literature 
(Sayre 1908), which described the pathology, the end-point, and accredited 
Volkmann for his scientific contribution. The new term became very popular with 
many authors (Thomas 1909) and was occasionally shortened to “Volkmann’s 
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paralysis” (Brooks 1922), or “Volkmann’s contracture” (Clarke 1946; Griffiths 
1940).  
By the middle of the last century, there had been increasing reports of 
cases of ACS, but with unusual presentations and different clinical scenarios, 
which was thought to be entities different from ACS. Therefore, special names 
were given to those conditions: e.g. “march gangrene” (Blandy and Fuller 1957) 
and exercise ischaemia” (Kirby 1970). Thus, the term “syndrome” started to 
appear in the literature reflecting the varied clinical picture, complexity of 
pathophysiology and systemic, as well as local consequences of ACS.  
In the English literature, the term “anterior tibial syndrome” (Carter 1949) 
appeared in a study analysing previous publication of two cases that had 
suffered necrosis of the anterior compartment muscles without any fractures: one 
had developed following a repair of muscular hernia, while the second one had 
been a soldier who had developed bilateral anterior tibial muscle necrosis 
following marching (Sirbu 1944). Mortez suggested the term “compartment 
ischemia syndrome” (Mortez 1953). Kunkel and Lynn, the Saskatoon surgeons, 
simplified the term to “compartment syndrome” (Kunkel and Lynn 1958). Matsen 
then successfully put forth all the published literature, attempting to understand 
the principal mechanisms behind the clinical presentations, and outlining the 
diagnostic and therapeutic rationale. The result was the unified concept of ACS 
(Matsen 1975). 
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1.1.4. Clinical Anatomy 
A compartment is a closed osseofascial anatomical space packed with 
muscles, nerves and vessels. The muscles in the extremities are arranged into 
groups, each enclosed within a fascial envelope (Ellis 2006). Each compartment 
has a limited capacity to accommodate a sudden increase in the volume of the 
contents, as happens when acute severe oedema or bleeding inside the 
compartment follow trauma (Matsen 1975). Knowledge of the surgical anatomy 
of the compartments is a paramount necessity for a safe and complete surgical 
decompression. In the leg, there are four distinct anatomical compartments: 
anterior, lateral, superficial posterior and deep posterior (Figure  1.1). 
 
1.1.5. Aetiology 
 Fractures cause 69% of cases of ACS, with tibial shaft fractures being 
the most common of all (McQueen, Gaston, and Court-Brown 2000). Soft tissue 
trauma is the second most common (23.2%) (McQueen, Gaston, and Court-
Brown 2000). Other causes of ACS include arterial injury, reperfusion injury, 
constrictive dressings and casts, bleeding disorders, injection injuries, burns, and 
infection (Donaldson, Haddad, and Khan 2014). The overall incidence of ACS 
following extremity trauma is 2.8% (Branco et al. 2011). 
 
1.1.6. Epidemiology 
ACS affects mainly young adults, but it has been reported in all ages, 
including children and neonates (Willis 2012; Ragland et al. 2005; Goubier, .  
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Figure 1.1. Anatomical compartments of the leg, shown at the level of the 
mid calf. 
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Romaña, and Molina 2005). 
The average age for males is 32 years, while that for females is 44 years 
(McQueen, Gaston, and Court-Brown 2000). It is estimated that 3.1 per 100,000 
of the population suffer compartment syndrome per year, men representing 91 % 
of cases (McQueen 2000). In the extremities, 75% of ACS affects leg 
compartments, 16% the forearm, 4% the hand, 3% the thigh, while only 1% is 
reported in the arm or the foot (Vaillancourt et al. 2004). 
 
1.1.7. Diagnosis 
The diagnosis of ACS is, essentially, a clinical skill; diagnosis can be 
confirmed by the measurement of intracompartmental pressure (Elliott and 
Johnstone 2003; Hargens et al. 1989; Matsen, Winquist, and Krugmire 1980). A 
high index of clinical suspicion helps in detecting early signs of ACS, before the 
irreversible damage occurs. ICP measurement is currently done using 
sophisticated digital pressure probes. 
Clinical findings include a swollen, tense, and tender compartment. 
Sensory deficits and motor weakness can be detected early, while paralysis 
occurs late in the presentation. The classical symptom is pain out of proportion to 
what would normally be expected from the existing injury, and is characteristically 
accentuated by passive stretch of the afflicted muscles (Hargens and Mubarak 
1998). The most striking sign is the presence of palpable distal arterial pulsation 
in most patients, contrary to cases of complete ischaemia (Whitesides and 
Heckman 1996). 
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1.1.8.  Intracompartmental Pressure (ICP) 
The pathognomonic factor in ACS is elevated ICP (Matsen 1975). The 
critical pressure threshold beyond which muscle cannot survive had been 
thoroughly investigated: an absolute compartment pressure of 30 mmHg had 
been suggested by some authors (Hargens et al. 1978; Mubarak et al. 1978; 
Mubarak, Pedowitz, and Hargens 1989; Hargens et al. 1981),  while 45 mmHg 
had been suggested by others (Rorabeck and Clarke 1978). Some also 
suggested calculating the difference between the mean arterial pressure and 
compartmental pressure, calling it the differential pressure (ΔP) (Heckman et al. 
1993; Hartsock et al. 1998; Mars and Hadley 1998; Heppenstall et al. 1988). A 
ΔP of 30 mmHg was found to impair muscle metabolism significantly at normal 
conditions, while a ΔP of 40 mmHg was found to cause similar effect in an 
injured muscle (Heppenstall et al. 1989). 
 
1.1.9. Fasciotomy 
The treatment in the late 1800s and early 1900s mainly addressed the 
complications of ACS rather than termination or prevention of the disease 
(Rowlands 1905; Sayre 1908). It was not until the mid 1970s that the literature 
showed general consensus on fasciotomy as the standard treatment for ACS 
(Willhoite and Moll 1970; Sheridan and Matsen 1976). 
Fasciotomy is a surgical procedure in which the fascial wall of the 
compartment is opened longitudinally, through a substantial surgical exposure, to 
fully decompress the contents (Mubarak and Owen 1977; Finkelstein, Hunter, 
9 
 
and Hu 1996) (Figure  1.2). Fasciotomy is the gold standard treatment of ACS 
and should be done as soon as the diagnosis is reached. 
 The most important predictor of outcome after ACS is time to fasciotomy. 
A significant progression of tissue injury and irreversible damage are very likely if 
elevated ICP persists for more than 6 hours (Rorabeck 1984; Sheridan and 
Matsen 1976; Elliott and Johnstone 2003).  In clinical practice, this critical period 
is called a ‘surgical window’. 
 Although fasciotomy is a limb saving procedure, it comes with its own 
complications. Even when carried out in a timely manner, the sequelae of ACS 
cannot be fully avoided in every case (Echtermeyer and Horst 1997; Giannoudis 
et al. 2002). Thus, there is a great need to find an adjunctive therapy, or 
alternative treatment to surgery, that can reduce complications, prolong the 
surgical window and improve the overall clinical outcome of the ACS. 
 
 
1.2. PATHOPHYSIOLOGY OF ACS 
 Pathophysiology of ACS appears to be very complex. Although there have 
been many research studies, explanations, and theories, it is not yet fully 
understood. The hallmark of compartment syndrome is the elevated ICP, with 
oedema as an essential cause.  
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Figure 1.2. Fasciotomy of the leg compartments. For a successful 
fasciotomy, all affected compartments should be decompressed by 
complete opening of the fascial envelope, including the deep ones, 
through a skin incision along the length of the compartment, taking 
care not to injure nerves and vessels. Following fasciotomy, all 
wounds should be left open to allow expansion of the oedematous 
muscles. Wound care protocols should be initiated, until delayed 
closure.  
AC, anterior compartment; LC, lateral compartment; DPC, deep posterior 
compartment; SPC, superficial posterior compartment. 
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1.2.1. Elevated ICP and Ischaemia 
 While the precise mechanism of muscle ischemia in ACS is elusive, it is 
widely accepted that it occurs mainly at the level of the microcirculation (Hartsock 
et al. 1998). Theories on the pathophysiology of ACS tried to explain how the 
elevated ICP would lead to ischaemia. Most of these considered only the 
mechanical force of elevated hydrostatic pressure as the cause of damage. The 
theories postulated that elevated ICP may result in ischaemia through an 
induction of arterial insufficiency, venous stasis, collapse of the capillaries, or a 
combination of these mechanisms (Murphy 1914; Brooks 1922; Jepson 1926; 
Griffiths 1940; Burton and Yamada 1951; Kinmonth 1952; Eichler and Lipscomb 
1967). Once ICP reaches a critical level above the perfusion pressure, it will lead 
to severe hypo-perfusion (Hartsock et al. 1998; Hargens and Mubarak 1998). 
 
1.2.2. Oedema and The Vicious Circle Concept 
Oedema commonly occurs following trauma, but it is particularly severe 
and rapidly progressive in ACS. While it is not known why oedema occasionally 
goes beyond the limits in certain cases, it is well-known that it leads to increased 
ICP to a level that triggers the occurrence of ACS.  
The self-perpetuating cycle is a plausible concept that could explain the 
relation between oedema and ICP. An increase in oedema would cause an 
increase in ICP, which would further increase the oedema and so on, leading to 
the establishment of ACS (Matsen and Clawson 1975) (Figure 1.3).  
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Figure 1.3. The vicious circle concept. Increased compartment pressure 
leads to an increase in tissue oedema, which, in turn, leads to 
increased compartmental pressure and so on. The process would 
be self perpetuating. Adapted from (Matsen and Clawson 1975). 
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1.2.3. Inflammation 
Echtermeyer questioned if the pathophysiology of ACS could only be 
explained by the high ICP (Echtermeyer and Horst 1997).  Experimental studies 
had suggested that cellular hypoxia during the phase of elevated ICP would 
induce a cascade of inflammatory reactions resulting in microcirculatory changes 
and tissue damage (Perler, Tohmeh, and Bulkley 1990; Sadasivan et al. 1997). 
Recently, inflammation was shown to play a major role in the induction and 
augmentation of cellular damage seen in ACS (Manjoo et al. 2010; Wang, 
Baynosa, and Zamboni 2011a; Gillani et al. 2012; Blaisdell 2002; Lawendy 
2014a).  Leukocytes (predominantly neutrophils) coupled with the production of 
pro-inflammatory mediators were found significantly contributing to the cellular 
damage (Lawendy, Sanders, Bihari, and Badhwar 2011; Lawendy, Sanders, 
Bihari, Parry, et al. 2011). 
It was not only local inflammation that had been observed in ACS, but also 
a systemic inflammatory response (Harvey et al. 2012; Lawendy et al. 2011; 
McGarr 2009; Lawendy 2014a). Our laboratory had previously shown that 
elevation of ICP led to a progressive sustained elevation in the serum tumor 
necrosis factor alpha (TNF-α), which further continued to increase, even at 45 
minutes after fasciotomy (Lawendy, Sanders, Bihari, Parry, et al. 2011; Lawendy 
et al. 2011; Lawendy et al. 2014). Lawendy et al also reported 7-fold increase in 
hepatocellular injury in an animal model of limb compartment syndrome 
(Lawendy 2014a, chap. 4). 
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1.3. ISCHAEMIA AND COMPARTMENT SYNDROME 
1.3.1. Compartment Syndrome versus Complete Ischaemia 
While tissue ischaemia is the common denominator of ACS and complete 
ischaemia, the elevated ICP creates a different pathophysiological state. ACS 
develops and progresses while arterial pulsation is still present, reflecting a 
unique ischaemic insult compared to complete ischaemia. 
 Heppenstall et al compared the pathological effects of complete 
ischaemia and compartment syndrome in a canine model (Heppenstall et al. 
1986). They elevated ICP for 3 hours, followed by 2 hours of reperfusion. The 
structural and metabolic deterioration of the skeletal muscle was then assessed. 
ACS was induced by autologous plasma infusion in the anterior compartment, 
while acute ischaemia was induced by a pneumatic tourniquet. The researchers 
reported a marked ultrastructural deterioration of skeletal muscle in ACS group 
compared to that observed in complete ischemia. They also demonstrated 
striking dissimilarities in the metabolic response between the two groups. The 
two most notable observations in the ACS group were the rapid depletion of 
adenosine triphosphate (ATP) levels and the marked intracellular acidosis 
compared the tourniquet group. In the complete ischemia group, ATP did not 
change at all throughout the experiment. Surprisingly, neither the acidosis nor the 
ATP levels recovered at 2 hours post-fasciotomy in the ACS group, while pH 
levels immediately recovered in the complete ischemia group following the 
release of tourniquet. The authors stressed the fact that in cases of ACS, there is 
always some degree of perfusion present  (Heppenstall et al. 1986). 
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1.3.2. Cellular Effects of Ischaemia 
Oxygen is fundamental to human physiology. While it is essential for 
mitochondrial ATP generation, ATP production is associated with the risk of 
oxidative damage; thus, oxygen concentrations must be tightly regulated 
(Semenza 1999). 
Oxygen deficiency during ischaemia results in the reduction of ATP 
production and acidosis due to accumulation of lactic acid from glycolysis. 
Sodium-potassium pumps are ATP dependent; therefore, during ischaemia the 
intracellular sodium and calcium are increased. This attracts water into the 
intracellular environment, causing cellular oedema. 
Ischaemia also promotes the production of pro-inflammatory substances, 
like leukocyte adhesion molecules, TNF-α and thromboxane A2. Additionally, 
ischaemia suppresses some ‘protective’ substances, like constitutive nitric oxide 
synthase (cNOS) and prostacyclin (Carden and Granger 2000). 
If ischaemia persists beyond the critical point of tissue tolerance, cellular 
necrosis becomes inevitable. While reperfusion is the only way to minimize 
ischaemic necrosis, it initiates tissue injury beyond that caused by the ischaemic 
insult alone. 
 
1.3.3. Limb Ischaemia-Reperfusion (IR) Injury 
Restoration of blood flow (reperfusion) to ischemic tissue is vital, but 
sudden reperfusion after a prolonged period of ischaemia is also deleterious 
(Lejay et al. 2014). The tissue damage caused by reperfusion was found to be 
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progressively proportionate to the time of reperfusion (Carmo-Araújo et al. 2007), 
and was estimated to be more than that caused by ischemia alone in the rat 
skeletal muscle (Loerakker et al. 2011). The main factors responsible for local 
and systemic damage caused by IR appear to be the reactive oxygen species 
(ROS) and activated neutrophils (Gillani et al. 2012).  
 Sudden supply of hypoxic tissue with oxygen leads to rapid formation of 
large quantities of ROS in the mitochondria, which exacerbates the mitochondrial 
dysfunction that had already started during ischaemia, by damaging the 
mitochondrial membrane. While mitochondrial function is to necessitate 
preservation of membrane potential (Wang et al. 2011), the IR damage leads to 
loss of this, leading to cessation of ATP production and producing cell necrosis. It 
also results in matrix swelling and eventual rupture of the mitochondrial 
membrane, releasing cytochrome c into the cytosol. This initiates apoptosis 
(Wang, Baynosa, and Zamboni 2011b). 
 
1.3.4.  Low-Flow Ischemia 
It has been known that the distal pulsation is intact in most cases of 
compartment syndrome. This may be interpreted as the ischaemia in ACS is not 
complete. Heppenstall et al stressed the fact that there was always some degree 
of perfusion in cases of ACS (Heppenstall et al. 1986). Lawendy et al have 
termed it ‘low-flow ischaemia’ (Lawendy 2014a).  
Conrad et al compared complete and incomplete ischaemia in a murine 
model. They reported marked early increase of a pro-inflammatory cytokine KC, 
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which is analogous to human Interleukin-8 (IL-8), in the partial ischaemia group 
(Conrad et al. 2005). Its early presence in partial ischaemia elucidated difference 
in pathophysiological sequences compared to complete ischaemia (Ghasemi et 
al. 2011). Lawendy et al also demonstrated significant early increase in the pro-
inflammatory TNF-α during the course of ACS, in contrast to complete ischaemia 
(Lawendy 2014a). 
 
1.3.5. ACS and IR Injury 
The severity of cellular damage reported in ACS appears to be more than 
that seen in complete ischaemia alone (Heppenstall et al. 1988; Heppenstall et 
al. 1989). This fact created a general impression that partial ischaemia is more 
damaging than complete ischaemia. However, recent studies reported that 
complete ischaemia causes more muscle damage than that caused by partial 
ischemia, contrary to what was generally believed (Conrad et al. 2005; Conrad et 
al. 2006). This new insight does not explain the extensive damage in ACS 
compared to complete ischaemia based on blood flow rate. Thus, there must be 
another mechanism. 
There are several pathological similarities between IR and ACS-induced 
striated muscle injury (Heppenstall et al. 1986; Sadasivan et al. 1997; Tollens, 
Janzing, and Broos 1998). The understanding that the reperfusion injury is more 
damaging than ischaemia itself may be the key to how to explain this puzzling 
fact (Loerakker et al. 2011). This compelled researchers to consider ACS as one 
of the clinical situations associated with skeletal muscle IR injury (Gillani et al. 
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2012), in which the reperfusion resulted in marked oxidative stress and an 
intense inflammatory response, thereby maximizing the local damage already 
caused by ischaemia, Additionally, it also induced a systemic inflammatory 
response (Carden and Granger 2000; Girn et al. 2007; Gillani et al. 2012). 
It should be remembered that ACS also results in a much greater level of 
metabolic strain and cellular deterioration than IR injury alone (Stephen R Kearns 
et al. 2010). Therefore, both ischaemia and IR may be concomitantly occurring in 
ACS. 
 
1.3.6. Fasciotomy and Reperfusion Injury 
Upon release of elevated ICP, Sadasivan et al reported no-reflow 
phenomenon, similar to that of IR injury (Sadasivan et al. 1997). Surgical 
decompression by fasciotomy promptly aborts the self-perpetuating cycle of 
oedema/elevated ICP by normalising the tissue pressure, thus saving the muscle 
by regaining blood supply. However, this leads to a sudden reperfusion of 
previously hypoxic tissues with oxygen-rich blood, producing an intense IR injury, 
mainly by the liberated ROS.  This effect is called a ‘second hit’ (Sellei, 
Hildebrand, and Pape 2014) which, in conjunction with the activated neutrophils, 
leads to  an increase in the microvascular dysfunction and the net tissue damage  
(Gillani et al. 2012). 
 Reperfusion injury normally occurs only after allowing normal blood flow 
to resume (for example, rearterization), which, theoretically, is what fasciotomy 
does in ACS. Still, this does not explain the early changes and damages seen 
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immediately following normalization of compartment pressure after 2 hours of 
experimental ACS (Sadasivan et al. 1997; Lawendy, Sanders, Bihari, Parry, et al. 
2011). 
 
1.4. PATHOLOGICAL FINDINGS IN ACS 
Apart from the myonecrosis, reported in ACS by most authors (Volkmann 
1881; Brooks 1922; Mabee and Bostwick 1993; Sheridan, Matsen, and Krugmire 
1977; Zimmerman and Shen 2013), recent researchers were able to visualise the 
in vivo changes occurring within the muscle immediately following fasciotomy in 
animal models. 
 
1.4.1. Microvascular Dysfunction 
Microcirculation is the part of blood circulatory system that provides 
skeletal muscles with oxygen and various nutrients, and removes the noxious 
waste products of metabolism (Hudlicka 2011). The vitality of the muscle, or any 
living tissue, depends on adequate perfusion through the capillary circulation. In 
normal physiological conditions, most capillaries are continuously perfused 
(CPC), with few intermittently perfused (IPC) or non-perfused (NPC) capillaries.  
Microcirculation is considered a ‘battlefield’ in inflammation and 
reperfusion (Wang, Baynosa, and Zamboni 2011a). Using the modern intravital 
video microscopy (IVVM) technology, researchers in our laboratory were able to 
elucidate the microvascular dysfunction associated with ACS, using a rat model 
(Lawendy, Sanders, Bihari, Parry, et al. 2011; Manjoo et al. 2010; McGarr 2009). 
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They reported significant reduction in the CPC, coupled with a significant 
increase in the NPC; in other words, there was a failure to restore the normal 
physiological micro flow. The microvascular dysfunction noticed in ACS was, to a 
great extent, similar to that reported in reperfusion injury following complete limb 
ischaemia, where the vascular bed behaves contrary to what is expected 
following re-establishment of the blood flow (Potter et al. 1993; Menger and 
Messmer 1993; Lam et al. 1994; Blaisdell 2002; Galiuto and Crea 2006; 
Maksimenko and Turashev 2012). A significant increase in the number of NPC 
causes an overall microvascular blood flow failure. This characteristic scenario is 
known as the ‘no-reflow phenomenon’ (Nanobashvili et al. 2003; Reffelmann and 
Kloner 2006). The main players responsible for the microvascular dysfunction 
appear to be ROS and activated leukocytes (Sadasivan et al. 1997; Gillani et al. 
2012; Blaisdell 2002).  
It worth mentioning that there are two distinct types of no-reflow: structural 
or otherwise irreversible, and functional (Galiuto and Crea 2006). The severity is 
related to the pathogenesis and duration of ischaemic insult (Reffelmann and 
Kloner 2006; Galiuto and Crea 2006). 
 
1.4.2. Tissue Injury 
Cellular injury is one of the earliest recognized sequelae of ACS. Studies 
have shown that tissue damage could be reverted by therapeutic modalities, 
implying that some damage may have been reversible (Lawendy et al. 2014; 
Manjoo et al. 2010). In vivo experiments in leukocyte-deplete rats have 
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demonstrated 50% reduction in cellular injury after 90 minutes of induced ACS 
(Lawendy 2014b), highlighting the important role of activated leukocytes in 
producing the cell damage. 
 Recent studies have shown that cell damage in IR injury is not just 
necrotic but, to a great extent, apoptotic, and appears to be induced by the effect 
of TNF-α (Sherwood and Toliver-Kinsky 2004). Apoptosis, in contrast to necrosis, 
is a programmed cell death process that can be triggered by several factors, but 
needs the caspases enzymatic pathway for apoptosis execution (de Nigris et al. 
2003; Haddad 2004; Riedl and Shi 2004; Nikoletopoulou et al. 2013). 
 
1.4.3. Leukocyte Activation 
Activated leukocytes tend to roll and adhere to the endothelium prior to 
transmigration through the vessel wall (Ley 2008).  Significant increase in 
leukocyte rolling and adhesion was reported in the post capillary venules of the 
skeletal muscle in a rat model of ACS (Lawendy et al. 2014; Manjoo et al. 2010; 
Lawendy 2014a; McGarr 2009). Leukocyte activation (rolling and adhesion) is 
controlled by differential expression of various adhesion molecules. 
 
1.5. MECHANISM OF INFLAMMATION IN ACS 
The literature reports of studies exploring the mechanism(s) of 
inflammation and tissue damage in ACS are scarce. However, mechanisms and 
pathways elucidated in IR injury can provide valuable insight on the possible 
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damaging and/or protective factors in ACS. There are enough similarities 
between IR injury and ACS to assume that both may be sharing some of these. 
 
1.5.1. Oxidative Stress 
1.5.1.1. Overview 
At normal conditions, aerobic metabolism within the mitochondria 
produces very active and potentially damaging ROS. These are potent oxidizing 
agents capable of cellular membrane lipid peroxidation and activation of 
neutrophils (Granger 1988). ROS are normally controlled by the natural 
antioxidant activity within the system. Oxidative stress is a state of imbalance 
between the pro-oxidants and antioxidants, in favour of the pro-oxidant (Ma, Qi, 
and Chen 2008; Ogura and Shimosawa 2014; Bar-Or et al. 2015). Several ROS 
may be involved in IR injury and ACS: superoxide anion (O2-), hydrogen peroxide 
(H2O2), hydroxyl radical (OH), hypochlorous acid (HOCl), and nitric oxide-
derived peroxynitrite (Perler, Tohmeh, and Bulkley 1990; Hancock, Desikan, and 
Neill 2001; C. Li and Jackson 2002). 
 
1.5.1.2. ROS in IR Injury 
ROS play an integral role in the progression of reperfusion injury, by 
inducing cell necrosis, apoptosis and activation of leukocytes (Hancock, Desikan, 
and Neill 2001; P. H. Chan 2001; C. Li and Jackson 2002; Wang et al. 2006; 
Arató et al. 2008; Wang, Baynosa, and Zamboni 2011b). NADPH oxidase and 
xanthine oxidase are perhaps two of the most important enzymes involved in the 
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generation of ROS (Hancock, Desikan, and Neill 2001), whereas superoxide 
dismutase (SOD) and glutathione peroxidase appear as two of very important 
defensive mechanisms to ameliorate the harmful effects of ROS. 
 
1.5.1.2.1. ROS in ACS 
ROS also appear to be important players contributing to the cellular 
damage in ACS. Ricci et al were able to markedly reduce the muscle damage of 
post-ischaemic ACS by administration of free radical scavengers in a canine 
model (Ricci et al. 1989). Likewise, Perler et al were able to inhibit the formation 
of compartment syndrome by ablation of free radical-mediated reperfusion injury 
(Perler, Tohmeh, and Bulkley 1990). 
 
1.5.2. Neutrophil Activation 
During reperfusion, activated leukocytes exhibit rolling behaviour, followed 
by firm adhesion to the endothelium of the post capillary venules. This creates 
favourable microenvironment permitting transmigration to the interstitial space 
(Weiss 1989). Upon activation, neutrophils release the contents of their 
intracellular granules containing ROS, cytokines, chemokines and proteolytic 
enzymes that mediate the injurious effects in reperfusion injury (Welbourn et al. 
1991; Hampton, Kettle, and Winterbourn 1998; Arnhold 2004; Klebanoff 2005; 
Robinson 2009). 
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1.5.3. Endothelial Dysfunction 
Endothelial dysfunction is one of the characteristics of IR injury. Upon 
exposure to ischaemia or reperfusion, the endothelium gets activated, creating a 
pro-inflammatory and pro-thrombotic surface, accompanied with loss of local 
vasodilation mechanisms. These changes collectively are termed endothelial 
dysfunction (Girn et al. 2007). The resulting vasoconstriction of the muscle 
microcirculation creates the known capillary no-reflow phenomenon (Wang et al. 
2005; de With et al. 2005). Reperfusion-induced vasoconstriction has been 
attributed to several factors, but recently was found to be caused by deficiency of 
endothelial nitric oxide synthase (eNOS) (but not the inducible nitric oxide 
synthase iNOS) (Wang, Baynosa, and Zamboni 2011b). 
 
1.5.4. Cytokines 
Cytokines are a group of signalling molecules that play an important role 
in modulation of the immune response (Cannon 2000; Zhang and An 2007). 
Almost all nucleated cells are capable of synthesizing cytokines and, in turn, 
respond to them (Dinarello 2000). Cytokines can regulate the expression of 
genes at the transcriptional level through selective alterations of expression of 
various transcription factors, thereby inducing the production of other cytokines 
and cell surface receptors. Additionally, they can also down-regulate themselves 
by a negative feedback loop (Grivennikov et al. 2006). 
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1.5.4.1. Pro-Inflammatory Cytokines  
Pro-inflammatory cytokines are involved in the upregulation of 
inflammatory mediators. TNF-α and Interleukin-1 (IL-1) are probably the most 
studied cytokines in IR injury. Both are produced at the site of local inflammation 
and their net effect is considered synergistic (Dinarello 2000). Interestingly, both 
exert similar roles but through different pathways and different receptors, 
showing a certain degree of redundancy (Dinarello 2000). TNF-α and IL-1 play 
important roles in downstream cytokine/chemokine-triggered leukocyte 
activation, production of endothelial adhesion molecules, stimulation of 
phagocytosis, and induction of apoptosis (Khan 2008). They also upregulate 
iNOS and induce transcription of cyclooxygenase-2 (COX-2), leading to an 
increase in prostaglandin-2 (PGE-2) synthesis (Zhang and An 2007; Dinarello 
2000). 
In ACS, a sustained elevation in TNF-α has been demonstrated during the 
period of elevated ICP, with a further, more pronounced increase following 
decompression (Lawendy et al. 2014). 
 
1.5.4.2. Anti-Inflammatory Cytokines 
These are immunoregulatory molecules that limit the potentially injurious 
inflammatory reaction due to the induction of the proinflammatory cytokines, if it 
becomes persistent or excessive (Opal and DePalo 2000). Their physiologic and 
pathologic roles are increasingly recognized in determining the outcome of 
disease by timely restoration of the proper balance. Molecules like IL-4, IL-10, IL-
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13, and transforming growth factor-β (TGF-β) can suppress the production of IL-
1, TNF-α, and vascular adhesion molecules; therefore, they are considered anti-
inflammatory cytokines (Dinarello 2000). 
 
 
1.5.4.3. Chemokines 
 Chemokines are cytokines that possess chemotactic properties attracting 
the circulating leukocytes towards the site of inflammation or injury (Sherwood 
and Toliver-Kinsky 2004). IL-8 is an example of a potent chemokine that 
specifically attracts neutrophils. Additionally, it is capable of stimulating their 
adherence to the endothelium of post capillary venule (Kobayashi 2006; Bickel 
1993). Neutrophil chemoattractant protein (KC) is the murine equivalent of 
human IL-8 (Conrad et al. 2005). 
 
1.5.5. Transcription Factors 
Transcription factors (TF) are proteins that control the copying of genetic 
material from DNA to the messenger RNA (Tjian 1996). This is done by the TF 
binding to a specific DNA region adjacent to the target gene. TF may increase or 
decrease the gene expression by activating or blocking RNA polymerase, the 
enzyme responsible for converting the DNA to messenger RNA (Schwabe, 
Rybakova, and Bruggeman 2012). 
Nuclear factor kappa-B (NF-κB) is a TF induced in response to a wide 
range of stimuli during IR injury, particularly oxidative stress and proinflammatory 
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cytokines (Nichols 2004; Lille et al. 2001). Activator protein-1 (AP-1) is another 
TF induced in a similar fashion (Lefler et al. 2002). Activation of NF-κB and AP-1 
in IR results in the upregulation of expression of various inflammatory molecules, 
including cytokines, adhesion molecules, and iNOS (Lefler et al. 2002; Nichols 
2004). 
 
1.5.6. Xanthine Oxidase 
Xanthine oxidase (XO) is an enzyme known to generate superoxide and 
hydrogen peroxide (J. K. Smith, Carden, and Korthuis 1989). Interactions with 
these two ROS can yield a range of cytotoxic agents, including hydroxyl radicals 
(Granger, Höllwarth, and Parks 1986; B. J. Zimmerman, Grisham, and Granger 
1990). XO-derived ROS are known to activate NF-κB leading to an upregulation 
of various inflammatory molecules. 
XO is produced by many tissues when subjected to IR insult, and is 
released in the systemic circulation (Tan et al. 1995). The circulating XO binds to 
the surface of endothelial cells and continues to produce oxidants. This, in turn, 
can trigger endothelial dysfunction, thereby contribute to the local damage, and 
cause remote organ injury (Pacher, Nivorozhkin, and Szabó 2006). 
NO has been shown to act as an endogenous suppressor of XO activity; 
thus, reduced level of the NO-mediated suppression of XO may result in 
increased superoxide generation (Ichimori et al. 1999; Pacher, Nivorozhkin, and 
Szabó 2006). 
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1.5.7. Caspases 
Caspases are a family of endoproteases that play a critical role in 
controlling inflammation and cell death. Activation of apoptotic caspases results 
in the generation of a cascade of signalling events that allows a controlled 
demolition of cellular components (McIlwain, Berger, and Mak 2013). This is how 
some caspases were given the nickname of ‘executioner’ proteins (Riedl and Shi 
2004). On the other hand, activation of inflammatory caspases results in the 
stimulation of innate immune responses, and the subsequent production of active 
proinflammatory cytokines (McIlwain, Berger, and Mak 2013). 
Recent evidence from experimental models of IR has shown that 
apoptosis doubled necrosis in skeletal muscle after 4 hours of ischemia and 24 
hours of reperfusion (Wang et al. 2008). 
 
 
1.5.8. Heme Oxygenase 
Heme oxygenase (HO) is an enzyme that degrades heme to biliverdin, 
iron and carbon monoxide (CO). There are two isoforms: the inducible HO-1 and 
constitutively-expressed HO-2. HO-1 functions as a ‘sensor’ of cellular stress, 
thus increasing cellular adaptation to stress and limiting tissue damage (Motterlini 
and Foresti 2014). 
The HO system has been shown to play important cytoprotective functions 
through the effects of its by-products. CO has been reported to diminish the 
severity of microvascular dysfunction and inflammation caused by ACS 
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(Lawendy et al 2014), while biliverdin and iron were found to be potent 
antioxidants (Ryter et al 2006). 
 
 
1.6. POTENTIAL NON-OPERATIVE TREATMENTS FOR ACS 
Apart from emergency surgical decompression and standard supportive 
treatment to prevent other systemic sequelae during the recovery period, few 
other treatment options exist for routine use in ACS (S. A. Olson and Glasgow 
2005). 
Adjunctive therapy is used together with the primary treatment to increase 
the chance of a cure, or to increase the efficacy of the primary treatment. In ACS, 
the primary treatment is the surgical decompression, and any medical or physical 
treatment given in conjunction with fasciotomy is considered adjunctive 
treatment.  
Since the cellular damage in ACS appears to be a result of intense 
ischaemia-induced inflammatory reaction coupled with oxidative stress, 
therapeutic modalities specifically targeting these factors may be beneficial in 
ACS as adjunctive treatment. 
 
1.6.1. Hyperbaric Oxygen 
Hyperbaric oxygen therapy showed promising results as an adjunct to 
fasciotomy, by decreasing complications from ACS. It has been shown to have 
the ability to reach ischaemic tissues suffering low perfusion during elevated ICP 
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state. Previously, it was found to be effective in reducing amputation rate and 
improving wound healing (Greensmith 2004; Strauss 2012). It has also been 
reported to reduce swelling, improve fasciotomy wound healing and fight 
infection (Weiland 2007). There is no large scale clinical study available on 
hyperbaric oxygen therapy in ACS, possibly because the very specialised 
equipment needed for it is not available in most trauma centres. 
 
1.6.2. Antioxidants  
Inhibition of ROS by strong specific antioxidants has proven to be 
successful experimentally in ablation of free radical-mediated reperfusion injury. 
Perler et al demonstrated that by scavenging the superoxide radical 
at reperfusion with SOD or blocking the hydroxyl radical formation with 
deferoxamine, a significant amelioration of the rise in compartment pressure 
could be achieved (Perler, Tohmeh, and Bulkley 1990). Vitamin C is also a 
powerful general antioxidant that concentrates preferentially in leukocytes. It has 
been tried experimentally in an animal model of ACS, and has been reported to 
attenuate the muscle injury (Kearns et al. 2004). 
 
1.6.3. Non-Steroidal Anti-inflammatory Drugs 
Anti-inflammatory drugs, in theory, may have therapeutic effect in ACS. 
Indomethacin, a strong anti-inflammatory drug, demonstrated protective effects in 
an experimental animal model of ACS (Manjoo et al. 2010). 
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1.6.4. N-Acetylcysteine 
N-acetylcysteine (NAC) has been shown to reduce the cellular damage 
due to production of free radicals from neutrophils, in an experimental animal 
model. It has been suggested that its activity may be due to the combined 
antioxidant and glutathione-replenishing activities ( Kearns et al. 2010). 
 
1.6.5. Gasotransmitters 
All cells in the living organisms are constantly receiving information about 
their surrounding environment necessary for the control and regulation of their 
activities, mediated by signalling molecules. Examples of these include 
hormones, neurotransmitters, pheromones, and cytokines. A class of small 
gaseous molecules have recently been discovered to function as signalling 
molecules; hence, they were termed ‘gasotransmitters’. There are three known 
gasotransmitters synthesized by mammalian cells: nitric oxide (NO), carbon 
monoxide (CO), and hydrogen sulfide (H2S) (Farrugia and Szurszewski 2014). 
There appears to be a considerable interplay among the members of the 
gasotransmitter family (Ling Li, Hsu, and Moore 2009; Whiteman and Moore 
2009). While signalling molecules usually require specialised receptors to evoke 
a response, gasotransmitters do not (Moody and Calvert 2011). Instead, they can 
freely permeate the plasma membrane and pass the message directly to an 
intracellular target (Rui Wang 2003). The use of these transmitters as a 
pharmacological agent in IR injury has gained a lot of attention in the last two 
decades (Moody and Calvert 2011). 
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1.6.5.1. Nitric Oxide (NO) 
NO was the very first gasotransmitter to be recognized. Its signalling role 
in the cardiovascular function as the endothelial-derived relaxing factor (EDRF) 
had been discovered by the 1998 Nobel Prize-winning work of Furchgott, Murad 
and Ignarro (The Nobel Foundation 2015). Since its discovery, NO has emerged 
as a fundamental signalling molecule responsible for the regulation of several 
cellular functions, as well as a potent mediator of cellular damage in a wide range 
of conditions (Pacher, Beckman, and Liaudet 2007). 
NO is synthesized from L-arginine by the enzyme NOS (Michel and Feron 
1997). It was identified as a strong vascular smooth muscle relaxant (Furchgott 
and Zawadzki 1980). Endothelial NOS (eNOS) is the isoform that plays a main 
role in vasorelaxation (Lamas et al. 1992). NO produced inside endothelial cells 
diffuses directly from the endothelium to the smooth muscle layer within the 
vascular wall, where it exerts its relaxing action (Dudzinski et al. 2006). 
NO has been reported to protect against ischaemic injury in the heart, 
brain, liver, and other tissues, when administered as a therapeutic agent 
(Siegfried et al. 1992; Hataishi et al. 2006). 
 
1.6.5.2. Carbon Monoxide (CO) 
 CO is a well-known toxic gas, recently identified as another 
gasotransmitter produced in humans (Marks et al. 1991). CO is produced 
endogenously through the activity of HO (Ryter and Otterbein 2004; Knauert et 
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al. 2013). Synthesis of CO has been shown to occur in almost all tissues (Maines 
1997). 
 CO, like NO, is also a known vasodilator, with direct effect on vascular 
smooth muscle (Kharitonov et al. 1995) and the central nervous system (Wiesel 
et al. 2001). It has been demonstrated to be involved in cell proliferation, 
inflammation, neurotransmission, mitochondrial biogenesis, autophagy and 
apoptosis (Brouard et al. 2000; Suliman et al. 2007; Knauert et al. 2013). 
 Cytoprotective effects of CO have been reported in several IR conditions, 
as well as in an animal model of ACS (Hangaishi et al. 2000; Yet et al. 2001; 
Tulis et al. 2001; Sato et al. 2001; Nakao et al. 2005; Ott et al. 2005; Scott et al. 
2009; Patel et al. 2012; Lawendy et al. 2014). It appears to act through different 
cytoprotective pathways, although the precise molecular interactions have not yet 
been fully elucidated (Knauert et al. 2013). 
Recent studies have demonstrated strong anti-inflammatory properties of 
CO.  One of the proposed pathways appears to be related to the activation of HO 
expression, which itself can decrease inflammation, and thrombosis (Patel et al. 
2012). CO also appears to inhibit the activity of NADPH oxidase, thus reducing 
the production of ROS. Finally, it is also a potent vasodilator, providing benefit by 
improving the microcirculation in IR injury (Motterlini and Otterbein 2010). 
Previously, our laboratory demonstrated that carbon monoxide, liberated 
from carbon monoxide-releasing molecule-3 (CORM-3), was able to mitigate the 
microvascular dysfunction and cellular injury in a rat model of ACS (Lawendy et 
al. 2014). 
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1.7. HYDROGEN SULFIDE  
Hydrogen sulfide gas (H2S) has long been known for its bad smell and 
toxic nature (Reiffenstein, Hulbert, and Roth 1992). Recently, it had been 
discovered that mammalian body can generate H2S endogenously, at cellular 
level, in many tissues and vital organs (Stipanuk and Beck 1982; Goodwin et al. 
1989; Hosoki, Matsuki, and Kimura 1997). The role of endogenously produced 
H2S has been suggested as an important signalling molecule, with invaluable 
cytoprotective functions  (Abe and Kimura 1996; Snijder et al. 2013; Kimura 
2014a; Hancock and Whiteman 2014). 
 
 
1.7.1. History of H2S 
 Bacterial activity has long been known to result in the production of 
hydrogen sulfide in the colon, producing gases with offensive smell (Suarez et al. 
1997), and, occasionally, in the oral cavity, resulting in halitosis (Suarez et al. 
2000). In contrast, the capacity of mammalian tissues to endogenously produce 
H2S became known only within the last century (Sluiter 1930; Meister, Fraser, 
and Tice 1954; Koj, Frendo, and Janik 1967). Surprisingly, H2S was considered 
as a by-product, rather than a physiologically active molecule, and thus has been 
largely ignored. 
 In the 1980s, the endogenous production of H2S started to grab the 
attention, after an in vivo rat study demonstrating mammalian tissue production 
under physiological conditions (Stipanuk and Beck 1982). Stipanuk and Beck 
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measured the concentration of H2S in different tissues and found it to be the 
highest in the liver, followed by the kidney; they also proved its presence in the 
heart, brain and skeletal muscle (Stipanuk and Beck 1982). While their work did 
not uncover the biological value of H2S, it was enough to hypothesize that there 
must be a physiological role for this compound. 
After analysing different biological processes in the brain, Abe and Kimura 
suggested that the endogenous H2S acts as a neuromodulator (Abe and Kimura 
1996). This observation was succeeded by several studies demonstrating the 
presence and biological value of H2S, in many organs and tissues. Soon after, 
H2S was reintroduced to the medical literature as a third gasotransmitter. 
Canadian scientists at the University of Saskatchewan then demonstrated 
that H2S significantly decreased blood pressure of rats, most likely through its 
relaxant effect on the vascular smooth muscle, and as an opener of KATP 
channels (Zhao et al. 2001). Such observations quickly made H2S a hot topic for 
active research, and highly raised its therapeutic expectations. 
 
1.7.2. Description 
H2S is an inorganic gas. It is colourless, flammable and heavier than air. 
The gas emits odour of rotten eggs at very low concentration, and is poisonous 
at high concentrations (Hughes, Centelles, and Moore 2009; Wedmann et al. 
2014). 
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1.7.3. Solution Chemistry of H2S 
H2S can freely penetrate the cell membranes of all tissues, without using 
any specific transporting system. It is soluble in water and plasma, and readily 
dissociates into hydrogen (H+) and hydrosulfide (HS-) ions (Fiorucci et al. 2006). 
Under normal physiological conditions, two thirds of H2S are dissociated (Kashfi 
and Olson 2013; Li and Moore 2008) as follows: 
H2S  ó   HS- + H+ 
H2S can reduce other compounds by simply giving away its H+; this 
property gives H2S the ability to directly reduce ROS, which would provide great 
value in cell protection. It is this property that gives it one of the most important 
proposed biological roles (Nagy et al. 2014). 
 
1.7.4. Toxicity 
The concentration of H2S in unpolluted air is very low, only 0.03 – 
0.1µg/m3.  The human nose is capable of detecting H2S when its concentration 
reaches 11µg/m3. However, when the concentration reaches 140mg/m3, the 
olfactory mucosa adapts, subjecting the person to inhalational toxicity.  A few 
breaths at a concentration of 700mg/m3 can be fatal (Chou et al. 2006). The 
cellular toxicity of H2S is attributed to its capacity to inhibit cytochrome c oxidase, 
the terminal enzyme of oxidative phosphorylation, producing cellular hypoxia 
(Koj, Frendo, and Janik 1967; Epithelium et al. 2002). 
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1.7.5. Endogenous Production of H2S 
H2S biosynthesis can occur via enzymatic and non-enzymatic pathways 
(Kolluru et al. 2013). 
 
1.7.5.1. Enzymatic Pathway 
 In mammals, H2S is synthesized from the sulfur-containing amino acids, 
cysteine and homocysteine, through the activity of four enzymes of three 
enzymatic pathways (Kashfi and Olson 2013; Kuksis, Smith, and Ferguson 2014) 
(Figure 1.4). Two pathways, believed to produce most of the endogenous H2S, 
are active in the cytosol: the cystathionine-β-synthase (CBS) and cystathionine-γ-
lyase (CSE). Both uses pyridoxal 5′-phosphate (vitamin B6) as a cofactor (Kolluru 
et al. 2013; Hughes, Centelles, and Moore 2009; Kimura 2014b). 
 The third pathway is mainly localized in the mitochondrial matrix, and 
occurs in a two-step reaction utilising 3-mercaptopyruvate sulfurtransferase (3-
MST) and cysteine aminotransferase (CAT) enzymes (Kodela, Chattopadhyay, 
and Kashfi 2012; Kimura 2014b). All three pathways are distributed across many 
tissues, and are often jointly present in many organs. CBS, highly expressed in 
the brain, produces H2S from cysteine (Abe and Kimura 1996).  CSE is 
expressed in the liver, pancreas, aorta, ileum, portal vein, and uterus (Kolluru et 
al. 2013; Kuksis, Smith, and Ferguson 2014), and also produces H2S from 
cysteine. The 3-MST is active in the brain and vascular system. 
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Figure 1.4. Enzymatic pathways of hydrogen sulfide production.. 
L-Cysteine can be converted to H2S via two P5P-dependent 
pathways. H2S synthesis via CSE also generates NH3 and 
pyruvate; synthesis of H2S via CBS generates L-serine. The P5P-
independent pathway (occurring primarily in mitochondria) is a 2-
step process: CAT converts L-cysteine to the intermediary, 3-
mercaptopyruvate, (depends on α-ketoglutarate). 3-
mercaptopyruvate is then converted 3-MST into H2S. 
CSE, cystathionine γ-lyase; CBS, cystathionine β-synthase; P5P, 
pyroxidal-5′-phosphate; CAT, cysteine (aspartate) 
aminotransferase; 3-MST, 3-mercaptopyruvate sulfurtransferase. 
Adapted from (Chan and Wallace 2013), with permission.  
39 
 
1.7.5.2. Non-Enzymatic Pathway 
The non-enzymatic production of H2S is less understood, and there is no 
general agreement about its value in the production of endogenous H2S. It 
occurs through direct reduction of elemental sulfur, and from dietary inorganic 
and organic sulfides (Papapetropoulos, Whiteman, and Cirino 2014; Kolluru et al. 
2013). Plants rich in dietary sulfides include Allium family; these have 
characteristic taste and smell (Munday 2012; Kuo, Chien, and Ho 1990). 
Allium vegetables (garlic, onion and shallots) have long been felt 
beneficial to health as an antioxidant. Recent evidence suggests that a number 
of beneficial effects of garlic may be derived from H2S production (Sener, 
Sakarcan, and Yegen 2007; Benavides et al. 2007; Y. Zhang et al. 2008; Namazi 
2008; Tsubura et al. 2011; Padiya et al. 2011). The beneficial effects of garlic in 
the prevention of IR injury have been reported in several organs (Namazi 2008). 
Garlic extract was also shown to vasodilate rat aorta via H2S production 
(Benavides et al. 2007). 
Allicin, diallyl disulfide and diallyl trisulfide in garlic extract are all 
considered H2S-donor compounds (Benavides et al. 2007; Kaschula et al. 2011). 
Under anoxic conditions, red blood cells were shown to produce H2S from the 
garlic extract within minutes (Benavides et al. 2007). Also, an increase in exhaled 
H2S levels was reported after infusion of diallyl disulfide in rats, thus providing an 
in vivo support for H2S production from garlic (Insko et al. 2009). 
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1.7.6. Release and Storage 
Despite the well-known enzymatic production pathways of H2S, the 
mechanisms of its release are not well understood. It is assumed that either H2S 
is released as soon as it is produced, or it is kept at intracellular stores, to be 
released in response to a physiologic signal (Ishigami et al. 2009). 
 
1.7.7. Metabolic degradation 
Degradation of H2S occurs in almost all tissues by mitochondrial oxidation; 
the process produces inactive sulphate, which is then excreted in urine. 
 
1.7.8. Plasma Level 
The normal, physiologic level of H2S in plasma is controversial (Olson 
2009). Some studies have reported values of 10 – 300µM, while others have 
concluded that circulating levels of H2S are negligible (Sparatore et al. 2009); 
thus physiological H2S may only act by means of autocrine or paracrine 
mechanisms (Whitfield et al. 2008). 
 
1.7.9. Physiologic Role 
H2S appears to plays a wide and varied physiological role (Kolluru et al. 
2013). It has been shown to regulate blood pressure (Yang et al. 2008), 
inflammation (Hu et al. 2007; Ling Li, Hsu, and Moore 2009; Dufton et al. 2012), 
and to act as a cell protector in oxidative stress (Kimura and Kimura 2004; 
Whiteman et al. 2005; Kimura et al. 2006; Wu et al. 2014). H2S has also been 
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reported as a neuromodulator (Whiteman et al. 2004), smooth muscle relaxant 
(Kimura 2010), learning and memory enhancer (Kimura 2002), aid in insulin 
secretion (Ali et al. 2007; W. Yang et al. 2005), and may even be involved in 
longevity (Kimura 2010). It may play a physiological role in many organ systems, 
including cardiovascular (Bucci and Cirino 2011; Al-Magableh, Kemp-Harper, 
and Hart 2015), respiratory (Kubo et al. 2007), digestive (Farrugia and 
Szurszewski 2014), brain and nervous system (B. H. Tan, Wong, and Bian 
2010), kidney (Lobb, Sonke, et al. 2014), liver (Mani et al. 2014), endocrine, 
reproductive (X.-Y. Zhu, Gu, and Ni 2011), and muscle (DU et al. 2013). 
H2S has been shown to be capable of exerting analgesic effects (Distrutti 
et al. 2006; Smith 2009; Lin et al. 2014; Donatti et al. 2014). Combining H2S with 
NSAIDs has opened new horizons for a safer and more effective results 
(McCarberg and Cryer 2014; Baskar et al. 2008; Chattopadhyay et al. 2012; 
Fiorucci, Santucci, and Distrutti 2007; Fomenko et al. 2014). 
One of the most interesting effects of H2S is the induction of a hibernation-
like state in mice, where the metabolic rate is dramatically reduced to less than 
10% of its normal hypothermic state. This has been termed ‘suspended 
animation’ (Blackstone, Morrison, and Roth 2005). The effect appears with the 
administration of sub-toxic concentration of inhalational H2S. The suspended 
animation state was shown to be highly protective against ischemic damage to 
cells by preserving mitochondria (Elrod et al. 2007; Blackstone and Roth 2007; 
Bos et al. 2009). 
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1.8. H2S AND IR INJURY 
The protective ability of H2S to reduce the extent of cellular damage in 
response to IR insult has been well documented by many researchers (Jha et al. 
2008; Calvert, Coetzee, and Lefer 2010; Henderson et al. 2010; King and Lefer 
2011; Lobb et al. 2012; Zhu et al. 2012; Lobb, Zhu, et al. 2014; Lobb, Sonke, et 
al. 2014). 
It appears that multiple pathways may be involved, as there is no known 
single mechanism that could explain all the cytoprotective effects of H2S: it was 
not possible to formulate a hypothesis of ‘one size fits all’ (Bos et al. 2014). 
 
1.8.1. Mitochondrial Protection 
H2S cytoprotective role appears to start at the level of mitochondria, 
through the inhibition of cytochrome c oxidase function. This would reduce 
respiration at mitochondrial level during IR, thus reducing the overproduction of 
ROS (Kimura et al. 2005; Wagner et al. 2009; Veeranki and Tyagi 2014). 
Mitochondrial protection may also be mediated by reducing membrane potential 
depolarization (Calvert, Coetzee, and Lefer 2010; Tang et al. 2013). 
 
1.8.2. Antioxidant Properties 
The anti-oxidant properties of H2S have been demonstrated by many 
researchers. H2S has been shown to diminish the production of ROS when 
administered at therapeutic doses (Calvert, Coetzee, and Lefer 2010; Chen et al. 
2006; Nicholson and Calvert 2010). The effect appeared to be mediated either by 
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directly scavenging ROS, or through indirect means, by upregulating intracellular 
antioxidants. 
H2S has been shown to induce the production of GSH, known for its 
potent antioxidant role (Kimura, Goto, and Kimura 2010; Bos et al. 2014). 
Alternatively, Sun et al observed reduction in the levels of ROS through inhibition 
of mitochondrial cytochrome c oxidase, and increasing activation of SOD (Sun et 
al. 2012). H2S also reported to reduce the oxidative stress by directly scavenging 
free radicals like superoxide and hydrogen peroxide (Geng et al. 2004), as well 
as the cytotoxic lipid oxidation products (Schreier et al. 2010; Calvert, Coetzee, 
and Lefer 2010), and the highly reactive peroxynitrite (Whiteman et al. 2004; 
Pacher, Beckman, and Liaudet 2007). 
 
1.8.3. Anti-Inflammatory Effects 
While the exact role of H2S in inflammation is not known, it has been a 
subject of several recent studies (Li and Moore 2008; R. Wang 2012). Whereas 
some have demonstrated clear anti-inflammatory effects of H2S, others also 
reported that it may be pro-inflammatory. Most of the evidence, however, points 
towards the anti-inflammatory properties of H2S (Chan and Wallace 2013). 
The results of Fiorucci et al  have shown that exogenous application of 
H2S was capable of inhibiting leukocyte adherence to the vascular endothelium 
by suppressing the expression of intercellular adhesion molecule-1 (ICAM-1) and 
leukocyte function-associated antigen-1 (LFA-1) (Fiorucci et al. 2005). H2S has 
also been shown to reduce production of pro-inflammatory cytokines and 
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chemokines, and assist the shift of macrophages to an anti-inflammatory 
phenotype (Wallace, Ferraz, and Muscara 2012; Dufton et al. 2012). In a rat 
model of colitis, H2S was found to reduce the levels of mucosal TNF-α (Bai, 
Ouyang, and Hu 2005). Inhibition of liver TNF-α has also been reported (Fiorucci 
et al. 2006). Moreover, H2S was shown to suppress NF-κB activation in the colon 
of patients suffering from ulcerative colitis (Bai, Ouyang, and Hu 2005). 
Suppressing NF-κB would, in turn, suppress the production of other inflammatory 
substances including cytokines, adhesion molecules, and iNOS (Lefler et al. 
2002; Nichols 2004). H2S also appears to reduce the progression of inflammation 
by enhancing the apoptotic death of polymorphonuclear leukocytes, thus limiting 
the neutrophil-mediated tissue injury (Mariggiò et al. 1998; Zanardo et al. 2006). 
Finally, H2S may exert some of its anti-inflammatory effects through 
upregulation of HO, which is known to reduce inflammation and exhibits 
cytoprotection by producing CO and bilirubin (Oh et al. 2006; Qingyou et al. 
2004; Ryter, Alam, and Choi 2006). 
 
1.8.4. Vasorelaxation 
H2S has been shown to exhibit potent vasodilator activity, both in vitro and 
in vivo (Bhatia 2005; Jackson-Weaver 2012; Stubbert et al. 2014). The effect 
appears to be through opening vascular smooth muscle KATP channels (Bhatia 
2005; Mustafa et al. 2011), and the inhibition of vascular tone (Jackson-Weaver 
2012). The vasorelaxation can be by both nitric oxide-dependent and 
independent means (Altaany et al. 2014; Holwerda, Karumanchi, and Lely 2015). 
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Like nitric oxide, the function of H2S is now considered as that of yet another 
major EDRF-like molecule, perhaps an endothelium-derived hyperpolarising 
factor (EDHF) (Mustafa et al. 2011; Tang et al. 2013). 
 
1.9. H2S IN EXPERIMENTATION 
1.9.1. Stimulation of Endogenous Production 
H2S is naturally produced in mammalian tissues; perhaps, for therapeutic 
or experimental examinations, one can attempt to boost its endogenous 
production instead of applying it exogenously. Garlic or allyl disulfide were used 
in several experiments as H2S-boosting substances, particularly in IR injury 
within the heart, kidney or the brain (Sener, Sakarcan, and Yegen 2007; 
Benavides et al. 2007). NAC and L-cysteine also function as precursors for the 
endogenous H2S synthesis (Caliendo et al. 2010). 
 
1.9.2. Inhibition of Endogenous Production 
Inhibition of endogenous production of H2S has been useful in studies 
examining its physiological role.  Currently, pharmacological inhibitors of the CSE 
enzyme are available, and genetically targeted CSE inhibition in mice is another 
available option (G. Yang et al. 2008; Sha et al. 2014). 
 
1.9.3. Exogenous Application of H2S 
There are several options available for the administration of H2S in 
experimental settings. Apart from H2S gas inhalation, H2S-donor compounds can 
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be used. These may come in the form of sulfide salts, synthetic moieties (slow-
releasing H2S donors) or hybrids of H2S donors.  
One major drawback in using sulfide salts (e.g. NaSH or Na2S) is the very 
rapid release and subsequent rapid decrease in H2S levels upon systemic 
administration; this makes it difficult to achieve controlled, stable and therapeutic 
levels in vitro or in vivo (Bos et al. 2014). 
On the contrary, slow-releasing H2S donors (the synthetic moieties), were 
developed to achieve stable release of H2S. These have been shown to release 
H2S in a slower and steady level following their administration (Ling Li et al. 
2007; Ling Li et al. 2008; Y. Zhao, Wang, and Xian 2011; Marutani et al. 2012; 
Predmore et al. 2012). GYY4137 (morpholin-4-ium-4-methoxyphenyl(morpholino) 
phosphinodithioate) is a water-soluble, slow-releasing H2S donor (Ling Li et al. 
2008). One millimole of GYY4137 releases approximately 40 micromoles of H2S 
within the first 10 min of activation, and then steadily continues to release H2S 
over a period of 3 hours. Systemic application of 133µmol/kg, either 
intraperitoneally (IP) or intravenously (IV), in rats was reported to increase 
plasma concentration of H2S from 32 µmol/l to 80µmol/l within 30 min; H2S 
remained elevated, at 50µmol/l, for further 3 hours (Kashfi and Olson 2013). In 
one in vitro study using human breast adenocarcinoma, a constant release of 
H2S for up to 7 days was noticed following addition of GYY4137 to cell culture 
media. They postulated that GYY4137 may accumulate inside cancer cells and 
thereby release larger amounts of  H2S intracellularly (Lee et al. 2011). 
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Hybrids of H2S donors are novel anti-inflammatory agents where the 
traditional NSAIDs are chemically modified to release H2S. Thus, these combine 
the cyclooxygenase (COX)-inhibitory activity with COX-independent anti-
inflammatory actions (Sidhapuriwala et al. 2007; Baskar et al. 2008; Zhang et al. 
2012; Chattopadhyay et al. 2013; Lee et al. 2013). 
 
1.10. STUDY MODELS FOR ACS 
1.10.1. Human Volunteers 
Studying ACS on humans is quite difficult, as the condition is potentially 
dangerous and permanent disabilities cannot be excluded. Moreover, it would be 
impossible to do certain in vivo studies on human the way it is done on laboratory 
animals like the intravital video microscopy (IVVM).  The literature on ACS is 
scarce of experimental studies done on living human volunteers. We are aware 
of only two published experiments; the first was performed using cylindrical air 
splints applied to the legs of three enthusiastic investigators  namely Frederick A. 
Matsen III,  Keith A Mayo, and Richard B. Krugmire, JR. (Matsen et al. 1977), 
while the second was performed on 10 volunteers by wearing anti-shock trousers 
(Willy et al. 2001). 
 
1.10.2. Animal Use 
Using animals for experimental studies on ACS was reported in the 1800s 
when Volkmann published his insight on the pathology of ACS pointing out to the 
data he got from animal studies (Volkmann 1881). Dogs, pigs, rabbits, mice and 
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rats are the common animals utilized by different researchers over the past 
century (Jepson 1926; Bardenheuer 1910; Heppenstall et al. 1986). Research 
studies on animals are just tools that may indicate a potential therapeutic benefit 
of any drug. Recognising and addressing the limitations of pre-clinical animal 
studies is a paramount for a successful translation of therapy from the bench to 
the bedside (Lotfi et al. 2013). 
 
 
1.10.2.1. ACS Rat Model 
Lawendy and his group have developed a clinically relevant model for 
ACS (Lawendy, Sanders, Bihari, Parry, et al. 2011). The model is relatively 
simple, in which normal saline infusion is used to elevate the ICP of the anterior 
compartment. It has been validated in several studies (Lawendy, Sanders, Bihari, 
Parry, et al. 2011; Lawendy et al. 2011; Lawendy, Sanders, Bihari, and Badhwar 
2011; Lawendy 2014a; Lawendy et al. 2015). 
Rats are good models of human disease with easy to monitor physiology 
(Iannaccone and Jacob 2009; Clause 1998). They are also easy to house and 
handle, relatively inexpensive, and readily available.  The suitable size of the rat, 
compared to the mouse, allows easy surgical fasciotomy and dissection of the 
skeletal muscle. The rat size also is quite suitable to be moved on the 
microscope for direct real-time visualization of the microcirculatory dysfunctions 
using the IVVM technology. 
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1.11. THESIS RATIONALE 
The ultimate goal of this study was to test a potential pharmacological 
therapy for ACS: a therapeutic option that could be used as an adjunctive 
treatment to the standard surgical decompression, capable of reducing the extent 
of tissue damage resulting from the ACS-induced ischaemic insult, or the 
subsequent reperfusion injury. 
  
1.11.1 Hypotheses 
1.11.1.1. The Effect of H2S on ACS 
The main objective of the thesis was to assess the therapeutic potentials 
of H2S in acute compartment syndrome. Based on previous studies in 
transplantation research or IR injury, it was hypothesized that H2S would also 
have a cytoprotective effect on the skeletal muscle in ACS.  
 
1.11.1.2. Combined CO/H2S Effect 
The second objective of this thesis was to explore the possible therapeutic 
effect of combining CO and H2S, as a possible adjunctive treatment of ACS.  
 It has been shown previously, in a rat model of ACS, that CORM-3-
derived CO could be beneficial in minimising the ACS-induced microvascular 
perfusion derangements, tissue injury and inflammation (Lawendy et al. 2014). 
However, to our knowledge, there have been no studies examining the combined 
effects of CO and H2S, whether in IR injury or transplantation surgery 
(Siriussawakul, Chen, and Lang 2012).  
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Both H2S and CO are lately-discovered gaseous signalling molecules. 
Their cytoprotective roles in IR injury has been documented in various organs 
and tissues (Ryter, Alam, and Choi 2006; Nicholson and Calvert 2010; Calvert, 
Coetzee, and Lefer 2010; Mancardi et al. 2009; Ozaki, Kimura, and Murase 
2012). Therefore, we hypothesised that combination of H2S and CO may have 
added protective benefit in ACS treatment, perhaps providing a synergistic 
therapeutic effect. In this study, we undertook to evaluate the cytoprotective 
potential of H2S in ACS in reference to the established results of CORM-3. 
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1. ANIMAL CARE 
All experimental protocols conducted in this study were approved by the 
Animal Use Subcommittee at the University of Western Ontario, London, 
Canada. The daily animal care, handling and housing were performed in 
accordance with the guidelines set out by the Canadian Council on Animal Care. 
All rats used for the experiments were housed in pairs, in clear plastic cages, 
under 12:12 light:dark cycle, and had access to food and water ad libitum. 
 
2.2. ANIMAL DESCRIPTION 
Twenty-five male Wistar rats, body weight 170–290 g, were used in the 
study. 
 
2.3. EXPERIMENTAL TREATMENT DRUGS 
Two treatment drugs were used in these experiments, plus an inert 
vehicle: hydrogen sulfide (H2S) and carbon monoxide (CO). 
 
2.3.1. Hydrogen Sulfide 
Hydrogen sulfide-releasing molecule, GYY4137 (Cayman Chemicals, Ann 
Arbor, Michigan, USA), was used at a dose of 50 mg/kg (Li et al. 2009). It was 
diluted in normal saline just prior to injection, and administered intraperitoneally 
to the designated group. Normal saline served as an inert vehicle (control). 
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2.3.2. Carbon Monoxide  
Carbon monoxide-releasing molecule-3 (CORM-3) was used at a dose of 
10 mg/kg (Lawendy et al. 2014). CORM-3 was synthesized in our lab, in 
accordance with the previously published method (Motterlini & Otterbein 2010), 
and was diluted it in normal saline just prior to injection to be administered 
intraperitoneally to the designated groups. 
Inactive CORM-3 (iCORM-3) served as an inert vehicle control; iCORM-3 
was prepared in the same manner as CORM-3, but was allowed to release all 
CO from the solution prior to being administered to the animals. 
 
 
2.4. EXPERIMENTAL SETUP 
2.4.1. General Overview 
Acute compartment syndrome (ACS) was experimentally generated in the 
rat hind limb under general anaesthesia. Elevated intracompartmental pressure 
was maintained at 30 - 40 mmHg for 2 hours, followed by fasciotomy and 30 
minutes of reperfusion time.  Intravital video microscopy (IVVM) was then 
performed. Experimental drug Injections were administered to all animals, as per 
the appropriate group, just before fasciotomy. Sham animals underwent all 
procedures, but the compartment pressure was maintained at a baseline level of 
0mmHg. 
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2.4.2. Anaesthesia 
Inhalational isoflurane was used to anaesthetize all animals. Induction of 
general anaesthesia was carried out by 5% isoflurane in a 1:1 mixture of oxygen 
and nitrogen gas, at a flow rate of 2L/min. Anaesthesia was maintained at 2% 
isoflurane, at a flow rate of 0.5L/min (Flecknell 1996), and adjusted as required to 
maintain the adequate anaesthetic depth. Left carotid artery was cannulated for 
the continuous monitoring of blood pressure, fluid replacement and arterial blood 
sampling. Rectal digital thermometer probe was used to continuously monitor the 
core body temperature; a constant core temperature of 37°C was maintained by 
the means of heating lamp. 
 
2.4.3. Acute Compartment Syndrome 
ACS was induced as previously described (Lawendy et al. 2011). Briefly, 
sterile isotonic saline solution (Baxter, Deerfield, IL) was continuously infused 
into the anterior compartment or the rat hind limb, elevating ICP via a 25-gauge 
needle (BD, Franklin Lakes, NJ).  ICP was measured by an electronic 
compartmental pressure monitoring system (Synthes, West Chester, PA), placed 
in the anterior compartment via a 14-gauge angiocatheter (BD). Saline infusion 
was carried out by gravity-feed system, with the saline bag elevated 120 cm 
above the working bench level. ICP was maintained at an average of 30 - 40 
mmHg for 2 hours (Figure 2.1). 
 
  
 	  
	  
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Experimental Setup in ACS. Saline is infused into the anterior 
compartment of the rat hind limb, elevating ICP to 30mmHg. ICP is 
continuously monitored by the use of electronic compartment 
pressure monitor, also inserted into the anterior compartment. 
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2.4.4. Fasciotomy 
 Following 120 minutes of elevated ICP, fasciotomy and exposure of the 
Extensor Digitorum Longus muscle (EDL) were undertaken, as previously 
described (Tyml and Budreau 1991; Lawendy et al. 2011). Briefly, the skin 
overthe lateral aspect of the leg was carefully incised, exposing the anterior and 
posterior compartments. The underlying biceps femoris muscle was partially 
incised to fully expose the tibialis anterior (TA), peroneus longus (PL) and lateral 
gastrocnemius muscles. Fasciotomy of the anterior compartment was carefully 
performed, taking care to avoid injury to the underlying muscles. EDL muscle 
was exposed by gentle separation of TA and PL, without physically touching its 
fibers. EDL tendon, identified at the ankle level, was tied using 3-0 silk ligature 
and cut as close as possible to the insertion. Following EDL preparation, animal 
was moved onto the stage of IVVM microscope, and the, EDL belly was partially 
reflected anteriorly into saline bath (Potter et al. 1993). 
 
 
2.5 EXPERIMENTAL GROUPS 
 Rats were randomly assigned to one of the five experimental groups: (1) 
Sham, (2) ACS, (3) H2S, (4) CO, (5) Combo.  
  
2.5.1 Sham 
All animals in this group (n=6) underwent all procedures, but the ICP was 
maintained at a baseline level of 0mmHg. 
 	  
	  
56 
2.5.2 ACS 
Animals in this group (n=5) underwent ACS, followed by inert vehicle 
injection at fasciotomy. 
 
2.5.3 H2S 
Rats (n=4) were subjected to ACS, and received GYY4137 injection at 
fasciotomy. GYY4137 served as a pharmacological means of hydrogen sulfide 
delivery. 
 
2.5.4 CO 
Animals (n=4) were subjected to ACS, followed by CORM-3 administration 
at fasciotomy. CORM-3 served as a pharmacological means of CO delivery, as 
previously described (Lawendy et al. 2014). 
 
2.5.5 Combo 
Animals in the combo group (n=6) were subjected to ACS, and received a 
combined treatment of both GYY4137 and CORM-3 at fasciotomy.  
 
 
2.6 INTRAVITAL VIDEO MICROSCOPY 
Rats under anaesthesia were carefully moved from the surgical bench to 
the stage of IVVM microscope. Extreme care was given to the dissected EDL, 
avoiding its being traumatised, twisted, stretched, or even touched by anything. 
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The muscle was then reflected onto a glass slide, into saline bath containing vital 
dyes. The EDL was then stabilized to the microscope stage using the attached 
silk ligatures, and covered with glass coverslip.  
 
2.6.1 Vital Dye Staining 
Two fluorescent vital dyes were used at a concentration of 5µg/mL each: 
ethidium bromide (EB) (Sigma Aldrich, Mississauga, ON), and bisbenzimide (BB) 
(Sigma Aldrich, Mississauga, ON). BB stains the nuclei of all cells, as it is a small 
enough molecule to readily permeate across the cell membrane. EB stains only 
the nuclei of injured/damaged cells, as its larger size requires compromised 
cellular membrane (Potter et al. 1995). Cellular injury was expressed as the ratio 
of ethidium bromide-labelled nuclei to bisbenzimide labelled nuclei (EB/BB). 
 
2.6.2 Microscopy 
Microvascular perfusion and leukocyte behaviour within the post-capillary 
venules were recorded by transillumination in five adjacent fields of view with 20x 
and 40x objectives, respectively (final magnification of 700x and 1400x). Under 
20x objective, each field of view contained a complete capillary bed, and was 
recorded for 60 seconds. Additional 10 seconds from the same fields of view 
were then recorded under the appropriate epifluorescence illumination, with the 
application of appropriate filters for BB (excitation wavelength=343nm, emission 
wavelength=483 nm) and EB (excitation wavelength=482 nm; emission 
wavelength=610nm). 
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Under the 40x objective, leukocytes were recorded within five randomly 
chosen post-capillary venules, with the approximate diameter of at least 20µm, 
for 45 seconds. All videos were captured into the computer using Adobe 
Premiere software for offline video analysis. 
 
 
2.7 OFFLINE VIDEO ANALYSIS 
2.7.1 Microvascular Perfusion 
Microvascular perfusion was quantified by counting the number of 
capillaries crossing three equidistant parallel lines drawn on the computer 
monitor, perpendicular to the capillary axis (Lawendy et al. 2014). Each capillary 
was categorized into one of three functional states: continuously-perfused (CPC), 
intermittently-perfused (IPC) and non-perfused (NPC). The results were 
expressed as percentage of total capillary count in the capillary bed, as per their 
functional state (De Backer et al. 2007)  
 
2.7.2 Injury Analysis 
Tissue injury was expressed as a ratio of EB-stained to BB-stained cells 
(EB/BB) (Potter et al. 1995). 
 
2.7.3 Analysis of Leukocytes 
Leukocyte behaviour was classified as the number of rolling or adherent 
leukocytes per 30 seconds in each capillary venule. An adherent leukocyte was 
defined as a cell that remained stationary for a minimum of 30 seconds (Granger 
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et al. 1989). The area of venules was measured using ImageJ software (NIH, 
Bethesda, MD). The results were expressed as number of 
leukocyte/30s/1000µm2  (Lawendy et al. 2011). 
 
 
2.8 TNF-α ELISA 
 Serum from animals was used to quantify systemic TNF-α levels at the 
following points: baseline (pre-ACS), 1 hour into ACS, 2 hours into ACS (just 
prior to injection and fasciotomy), 10 minutes post-fasciotomy, 20 minutes post-
fasciotomy, 30 minutes post-fasciotomy and 45 minutes post-fasciotomy. Serum 
was obtained by allowing the whole blood to coagulate at room temperature for 
30 minutes, followed by centrifugation at 1500xg for 20 minutes at 4°C. The 
supernatants (serum) were collected and stored at -80°C. 
 Levels of TNF-α were assessed using enzyme-linked immunosorbent 
assay (ELISA) kit (Pierce Biotechnology, c/o Thermo Scientific, Rockford, IL), as 
per manufacturer’s instructions. The assay was sensitive to less than 5pg/ml. 
 All samples were run in duplicate. Standard curve was obtained by 
performing serial dilutions of reconstituted lyophilized TNF-α standard; 
2,500pg/ml, 833pg/ml, 500pg/ml, 278pg/ml, 93pg/ml, 31pg/ml and 0pg/ml were 
used to obtain the standard curve. Serum samples were diluted at 1:1 ratio with 
sample diluent buffer. All plate incubations were carried out at room temperature. 
Fifty µl of each sample or standard were added to the appropriate designated 
wells on a 96-well plate, and incubated for 1 hour. After three washes, 50µl 
biotinylated TNF-α antibody was added to each well and incubated for 1 hour. 
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Following three washes, 100µl streptavidin-HRP reagent was added to each well 
and incubated for 30 minutes. After the final three washes, 100µl tetramethyl 
benzidine (TMB) substrate was added to each well and the plate was incubated 
for 10 minutes in the dark. 100µl stop solution was used to stop the reaction. The 
absorbance was read on microplate reader (model 680, BioRad) at 450nm. The 
results were calculated by 4-point logistic curve fitting software against TNF-α 
standard. 
 
 
2.9 STATISTICAL ANALYSIS 
All data was analyzed using analysis of variance (ANOVA), with Newman-
Keuls multiple comparison post-hoc test where appropriate. Two-way ANOVA 
was used to analyse the systemic TNF-α levels (pre- and post-treatment), while 
one-way ANOVA was used to analyse the rest of the results. Statistical 
significance was defined as p<0.05. Data analysis was performed using Prism 
version 4.0c for Mac (GraphPad Software Inc., San Diego, CA). 
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CHAPTER 3. RESULTS 
3.1. MICROVASCULAR PERFUSION 
3.1.1. Continuously-Perfused Capillaries (CPC) 
Elevation of ICP resulted in a significant decrease in the CPC, from 
75±2.6% in the sham to 48±5% in the ACS group (p<0.01). Hydrogen sulfide 
treatment (H2S group) led to a significant increase in CPC from ACS, to 
66.4±13.3% (p<0.05). The CPC in both the CO and Combo groups also 
significantly increased, compared to ACS group (62.7±4.8%, p<0.05 and 
69.8±11%, p<0.01, respectively). There was no significant difference in the CPC 
between H2S, CO and Combo groups compared to sham (Figure 3.1). 
 
3.1.2. Intermittently-Perfused Capillaries (IPC) 
There were no significant differences in IPC in any of the groups, although 
there was a trend towards an increase in the ACS group 
 
3.1.3. Non-Perfused Capillaries (NPC) 
 Elevation of ICP led to a significant increase in NPC, from 10.6±1.3% in 
sham to 29.9%±5.3% in ACS group (p<0.001). Hydrogen sulfide treatment (H2S 
group) led to a significant decrease in NPC to 16.5±2.7% (p<0.05) when 
compared to ACS group. Both CO and Combo treatments resulted in a 
significant reduction in NPC, to 16.4±1.1% (p<0.05) and 18±1.9% (p<0.01), 
respectively, compared to ACS group (Figure 3.1). There were no significant 
differences in NPC between H2S, CO, Combo and sham groups (Figure 3.1). 
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Figure 3.1 The Effect of H2S on Skeletal Muscle Perfusion Following ACS.  
ACS resulted in a significant microvascular dysfunction; H2S 
partially restored the perfusion, similar to that of CO or combination 
of H2S and CO (Combo). CPC, continuously perfused capillaries; 
IPC, intermittently perfused capillaries; NPC, non-perfused 
capillaries (*p<0.001 from sham; †p<0.05 from ACS). 
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3.2.  TISSUE INJURY 
Elevation of ICP caused a significant increase in tissue injury, from 
0.09±0.02 in sham to 0.33±0.02 in ACS group (p<0.001). Hydrogen sulfide 
treatment (H2S group) resulted in a significant decrease to 0.14±0.07 (p<0.001), 
compared to ACS group. Both CO and Combo groups also displayed a 
significant reduction in the tissue injury (0.16±0.07, p<0.01 and 0.13±0.01, 
p<0.001, respectively), compared to ACS group (Figure 3.2). There were no 
significant differences in the tissue injury between H2S, CO, Combo or sham 
groups (Figure 3.2). 
	  
3.3.  LEUKOCYTE BEHAVIOUR 
3.3.1. Leukocyte Rolling 
Elevation of ICP resulted in a significant increase in leukocyte rolling, from 
1.33±0.29 leukocytes/30s/1000µm2 in sham to 4.55±1.49 
leukocytes/30s/1000µm2 in ACS group (p<0.05). Hydrogen sulfide treatment (H2S 
group) led to a significant reduction in leukocyte rolling to 1.82±0.51 
leukocytes/30s/1000µm2 (p<0.05), compared to ACS group. Both CO and 
Combo treatments also led to a significant decrease in leukocyte rolling 
(0.82±0.12 leukocytes/30s/1000µm2 and 1.17±0.3 leukocytes/30s/1000µm2; 
p<0.05, respectively) when compared to ACS group. There were no significant 
differences in leukocyte rolling between H2S, CO, Combo, and sham groups 
(Figure 3.3). 
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Figure 3.2 The Effect of H2S on Skeletal Muscle Tissue Injury Following 
ACS. ACS resulted in a significant increase in tissue injury; H2S 
significantly diminished the ACS-induced injury, similar to that of 
CO or combination of H2S and CO (Combo) (*p<0.001 from sham; 
†p<0.01 from ACS). 
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Figure 3.3. The Effect of H2S on Leukocyte Activation Following ACS: 
Leukocyte Rolling. ACS led to a significant increase in leukocyte 
rolling; H2S attenuated this response, similar to that of CO or 
combination of H2S and CO (Combo) (*p<0.05 from sham; †p<0.05 
from ACS). 
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3.3.2. Leukocyte Adhesion 
Elevation of ICP resulted in a significant increase in leukocyte adhesion, from 
0.83±0.16 leukocytes/30s/1000µm2 in sham to 4.49±0.79 
leukocytes/30s/1000µm2 in ACS group (p<0.001). Hydrogen sulfide treatment 
(H2S group) led to a significant decrease to 0.89±0.20 leukocytes/30s/1000 µm2 
(p<0.001), compared to ACS group. Both CO and Combo groups also displayed 
significantly lower leukocyte adherence compared to ACS group (1.29 ± 0.25 
leukocytes/30s/1000 µm2 and 0.67±0.16 leukocytes/30s/1000 µm2, p<0.001, 
respectively). There were no significant differences in leukocyte adhesion 
between H2S, CO, Combo, and sham groups (Figure 3.4). 
 
 
3.4     SYSTEMIC TNF-α LEVELS 
 Elevation of ICP resulted in a continuous, sustained increase in systemic 
levels of cytokine TNF-α, from the baseline of 1.3±1.5pg/ml to 558.8±202.6pg/ml 
and 1222.9±591.5pg/ml at 1hr and 2hr ACS, respectively (Figure 3.5). Following 
fasciotomy, TNF-α levels continued to increase to 2834.38±730.1pg/ml at 45 
minutes post-fasciotomy. Hydrogen sulfide treatment (H2S group) led to a 
significant reduction in systemic TNF-α levels to 893.7±450.4pg/ml, 
588.7±398.5pg/ml, 454.7±253.4pg/ml and 205.3±112.7pg/ml at 10min, 20min, 
30min and 45min post-fasciotomy, respectively (p<0.05 from ACS alone). Combo 
treatment resulted in an almost immediate significant reduction in systemic TNF-
α levels to 31.8±26.84pg/ml, 17.2±10.9pg/ml, 8.9±10.8pg/ml and 7.0±4.9pg/ml at  
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Figure 3.4. The Effect of H2S on Leukocyte Activation Following ACS: 
Leukocyte Adhesion. ACS led to a significant increase in 
leukocyte adhesion; H2S attenuated this response, similar to that of 
CO or combination of H2S and CO (Combo) (*p<0.05 from sham; 
†p<0.05 from ACS). 
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Figure 3.5. Effect of H2S on Systemic TNF-α levels in ACS. ACS led to 
significant increase in systemic TNF-a levels; H2S injection at 
fasciotomy diminished this response, similar to that of combination 
of H2S and CO (Combo) (*p<0.05 from baseline; †p<0.05 from ACS 
alone). 
 
 	  
	  
69 
10min, 20min, 30min and 45min post-fasciotomy, respectively (p<0.001 from 
ACS alone). There was no statistical difference between H2S and combo groups 
(Figure 3.5). 
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CHAPTER 4. DISCUSSION 
 
4.1  GENERAL OVERVIEW OF COMPARTMENT SYNDROME 
ACS is a known surgical emergency in which the viability of the 
compartment contents are endangered by the persistence of elevated ICP. The 
local and systemic outcome of untreated ACS may be catastrophic (Defraigne & 
Pincemail 1998; Bocca et al. 2002; Ritenour et al. 2008; Hershey 2013; Bonnaig 
et al. 2014). Fasciotomy remains the only gold standard treatment, and should be 
performed as soon as the diagnosis is reached; yet, it comes with its own 
complications, and the sequelae of ACS cannot be fully avoided (Echtermeyer & 
Horst 1997; Giannoudis et al. 2002). 
The pathophysiology of ACS appears to be complex and still not yet fully 
understood. While there has been general agreement that the cellular damage 
occurs at the microcirculation level, there has been disagreement on the 
pathomechanisms of this damage (Ashton 1962; Matsen 1975; Whitesides et al. 
1975; Ashton 1975; Matsen et al. 1979; Reneman et al. 1980; Heppenstall et al. 
1988; Matsen & Rorabeck 1989; Perler et al. 1990; Hartsock et al. 1998). 
 
4.1.1  ACS as a Low-Flow Ischaemia 
 Elevation of ICP in ACS does not appear to cause complete ischaemia 
(Heppenstall et al. 1986), but rather a low-flow ischaemia (Lawendy 2014). Even 
though, ACS causes more ultrastructural damage in skeletal muscle compared to 
complete ischaemia (Heppenstall et al. 1986; Heppenstall et al. 1988; 
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Heppenstall et al. 1989). While ACS and partial ischaemia share a unique 
temporal and qualitative patterns of cytokines expression compared to complete 
ischaemia (Conrad et al. 2006; Lawendy et al. 2014), partial ischaemia causes 
less muscle damage than complete ischaemia (Conrad et al. 2006). These 
puzzling observations raised the question if the damage in ACS could only be 
explained based on the magnitude of ischaemia resulting from high ICP 
(Echtermeyer and Horst 1997). On the other hand, several pathological and 
biochemical similarities have been found between ACS and IR injury including 
the induced microvascular dysfunctions in the skeletal muscle and early intense  
inflammatory response (Heppenstall et al. 1986; Sadasivan et al. 1997; Tollens 
et al. 1998; Loerakker et al. 2011; Lawendy, Sanders, et al. 2011; Lawendy et al. 
2014; Zhao et al. 2014), and thus compelled researchers to consider ACS as one 
of the clinical situations associated with skeletal muscle IR injury (Gillani et al. 
2012). 
This new insight, considering both ischaemia and IR injury are occurring in 
ACS, could explain the mystifying fact that the observed damage in ACS is 
usually beyond that of ischaemic one. In orthodox thinking, the expected 
scenario would be an ischaemic insult during the phase of elevated ICP and IR 
injury after fasciotomy, as normalizing the ICP by fasciotomy allows the 
oxygenated blood to flow to the ischaemic muscles. Whereas this sounds a 
logical scenario, it does not explain the IR-like microvascular dysfunctional 
changes observed immediately following fasciotomy (Sadasivan et al. 1997; 
Lawendy, Sanders, et al. 2011) compared to 3 hours of reperfusion following 
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complete ischaemia (Olivas et al. 2001). These aforementioned observations led 
us to assume that IR injury could be happening concomitantly during the course 
of elevated ICP and become maximized after fasciotomy. The mechanism of 
occurrence of IR injury during the phase of elevated ICP may need to be 
evaluated experimentally.  
Hargens et al (1981) stated that it was unknown how much microvascular 
occlusion and reduced flow exist at a tissue pressure of 30 mmHg or greater 
after studying pressurized canine leg compartments using technetium-99m 
(Hargens et al. 1981). Hartsock et al (1998) have shown significant decreases in 
the number of perfused capillaries as tissue pressure became progressively 
elevated during in vivo video microscopy of the rat cremaster muscle (Hartsock et 
al. 1998). From these findings, it was clear that microcirculation dose not cease 
completely or uniformly in the muscle as the ICP rises.  
The low-flow ischaemia occurring in ACS should not be considered as a 
low-degree of global muscle ischemia, but rather a heterogeneous or mal-
distributed blood flow pattern in the muscle, as described by Sadasivan et al 
(1997). Elevated ICP may be creating a differential state of microvascular 
dysfunctional where some micro areas within the muscle are suffering severe 
ischaemia, while others are better perfused. Endothelium and leukocytes would 
quickly become activated in the ischaemic milieu. The non-perfused and 
perfused areas may physiologically alternate by selective arteriolar response, as 
a protective mechanism against ischaemic necrosis, or due to changes in 
interstitial fluid distribution. Allowing blood to flow in the previously non-perfused 
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micro areas would then create a limited micro-reperfusion injury. Occurrence of 
multiple micro-reperfusions would release the pro-inflammatory cytokines and 
ROS that are known to cause capillary leak and tissue oedema, leading to an 
increase in tissue pressure, resulting in more micro areas of non-perfused 
muscle, thus initiating the known theory of vicious cycle.  
While the sudden supply of acutely ischaemic tissue by oxygenated blood 
is the common known cause to induce IR injury, non-acute hypoperfusion 
situations also display a form of continuous and recurrent IR injuries. For 
example, in peripheral arterial disease, where there is a long standing 
hypoperfusion of the limb muscles, IR injuries with release of ROS have been 
reported on walking (Ciuffetti et al. 1991; Hickman et al. 1994; Dopheide et al. 
2013; Hiatt et al. 2015). IR injury has even been blamed also for chronic non-
healing wounds (Mustoe et al. 2006), and the pathogenesis and progression of 
diabetic ulcers (Alavi et al. 2014). These findings strengthen our assumption of 
concomitant occurrence of ischaemia and IR in ACS during elevated ICP phase. 
Recently, experimental studies have shown that ACS induces a cascade 
of inflammatory reactions, resulting in microcirculatory changes and tissue 
damage (Perler, Tohmeh, and Bulkley 1990; Sadasivan et al. 1997; Manjoo et al. 
2010; W. Z. Wang, Baynosa, and Zamboni 2011a; Gillani et al. 2012; Blaisdell 
2002; Lawendy 2014; Lawendy et al. 2015).  Several pro-inflammatory mediators 
and ROS are known to be released during this process, resulting in 
microcirculatory dysfunction, leukocyte activation and cell damage (Menger et al. 
1992; Sadasivan et al. 1997; Tollens, Janzing, and Broos 1998; Lawendy, 
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McGarr, et al. 2011; Gillani et al. 2012). Although timely fasciotomy saves limbs 
from further ischaemic insult, it does not address the inflammatory element 
resulting from the ischaemia itself or from the IR injury. Moreover, the sudden 
reperfusion, induced by fasciotomy, probably causes the so called ‘second hit’ 
(Sellei et al. 2014), where ROS increase the microvascular dysfunction and 
maximizes the net tissue damage (Gillani et al. 2012). 
 
4.1.2  The Search for the Magic Bullet 
Although ACS contributes significantly to morbidity and mortality by 
inducing an array of ischaemic and intense inflammatory response, there has 
been little progress made towards development of translatable therapeutic 
interventions that might ameliorate ACS sequelae. A therapeutic intervention 
capable of changing the biochemical environment during the elevated ICP and/or 
following fasciotomy would be of significant benefit (Henderson et al. 2010). 
Cellular damage in ACS appears to be a result of intense ischaemia-
induced inflammatory reaction, coupled with oxidative stress; thus, targeting 
these factors may be beneficial. The ideal adjunctive therapy should be able to 
either prevent the progress of ACS (perhaps by enhancing ischemic tolerance of 
the tissue), or at least reduce the damage caused by oxidative stress and 
inflammation. The final outcome would be a reduction in the need for surgery, 
improvement in function, and fewer systemic complications. Additionally, the 
post-fasciotomy muscle oedema would be diminished, allowing for an easier 
delayed wound closure, without the need for skin grafting. 
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There is a marathon race toward discovering pharmacological agents 
capable of blocking or ameliorating the damages in ACS. Research in 
transplantation surgery and ischaemic heart disease has enriched the body of 
knowledge in the quest for the potential therapeutic agents in IR.  Our laboratory 
has previously shown the efficacy of carbon monoxide (CO) and indomethacin in 
mitigating the damaging effects of ACS on skeletal muscle (Lawendy et al. 2014; 
Manjoo et al. 2010). This led us to the current work, the purpose of which was to 
evaluate the role of H2S in ACS. 
 
 
4.2  EFFECTS OF ELEVATED ICP  
 We found that elevation of ICP resulted in a significant local effects on 
skeletal muscle, as demonstrated by the microvascular perfusion changes 
(Figure 3.1), tissue injury (Figure 3.2) and leukocyte activation (Figures 3.3. and 
3.4). We also demonstrated systemic effects of elevated ICP as demonstrated by 
increased TNF-α level (Figure 4.5). 
 
4.2.1.  Perfusion Changes 
Significant increase in the number of non-perfused capillaries appears to 
be a consistent finding in ACS ( Lawendy, Sanders, et al. 2011; Manjoo et al. 
2010; McGarr 2009). This observation resembles the no-reflow phenomenon 
associated with the IR injury. 
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Using the modern technology of IVVM, direct visualisation of the skeletal 
muscle microcirculation has demonstrated a failure to restore the normal 
physiological micro-flow following fasciotomy (Figure 3.1). Consistent with 
previous studies, this hypoperfusion was evidenced by significant increase of 
NPC coupled with significant decrease in CPC (Manjoo et al. 2010; Lawendy, 
Sanders, et al. 2011; Lawendy et al. 2014; Lawendy 2014; Lawendy et al. 2015). 
Microcirculatory studies of IR described this failure of capillary perfusion 
as ‘no-reflow’. It had been demonstrated in several organs, such as the brain  
(Ames et al. 1968), skeletal muscle (Blaisdell 2002),  kidney (Summers & 
Jamison 1971), and even skin (Chait et al. 1978). The occurrence of no-reflow 
would lead to focal ischemia and hypoxia, and despite normalization of 
compartment pressures, it would reduce recovery in muscle and increase the 
damage. The decrease in CPC was reported to correlate well with the increase in 
tissue necrosis in IR injury (Olivas et al. 2001). 
The complexity of the pathogenesis of no-reflow is not completely 
understood (Durante & Camici 2015). No-reflow could be either a functional 
disturbance of microcirculation caused by vasoconstriction (Galiuto & Crea 2006; 
Maksimenko & Turashev 2012), or structural change caused by luminal blocking 
by aggregates of erythrocytes or leukocytes with platelets (Jaffe et al. 2008; 
Niccoli et al. 2008). While the functional no-reflow is a potentially reversible 
process, tissue injury may become irreversible after the 7- 8 hour interval (Olivas 
et al. 2001). 
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Our data displayed considerable deterioration of the perfusion following 
ACS, as seen at 30 minutes post-fasciotomy (Figure 3.1). There was a significant 
increase in the non-perfused capillaries, and a significant reduction in 
continuously perfused capillaries, consistent with what had been reported in 
previous publications. Thus or data confirmed the hypoperfusion state/the no-
reflow phenomenon seen after fasciotomy (Lawendy 2014; Lawendy, Sanders, et 
al. 2011). The decrease in CPC was found to correlate well with the increase in 
percentage of tissue damage (Figure 3.2), consistent with what previously found  
(Olivas et al. 2001). 
Although there are great similarities noticed between the no-reflow 
phenomenon reported in ACS and that reported in IR injury following complete 
ischaemia, there are clear temporal and qualitative differences. While we 
reported significant decrease in CPC after only 30 minutes of fasciotomy, a 
similar significant decreases was reported after 3 hours of reperfusion after 
complete ischaemia (Olivas et al. 2001). 
 
4.2.2  Tissue Injury 
 Our data demonstrated a significant cellular injury after 2 hours of 
elevated ICP (Figure 3.2). We reported 33% cellular injury, compared to 9% seen 
in sham. This was consistent with the previously reported cellular injury ratio 
(Manjoo et al. 2010; Lawendy, Sanders, et al. 2011; Lawendy et al. 2014). 
These data are also consistent with previous studies demonstrating an 
increase in tissue necrosis due to IR but with different temporal and qualitative 
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patterns, as we reported significant tissue injure after 30 minutes of fasciotomy, 
while it required 7 hours of reperfusion to show significant tissue injury after 3 
hours of complete ischaemia  (Olivas et al. 2001). 
 Cellular death appears to be the net result of all destructive mechanisms 
involved in pathophysiology of ACS. Cell necrosis has long been considered to 
be the natural fate of ischaemic insult. Recent evidence from experimental 
models indicates that apoptosis is a major contributor to IR-induced cell death 
(Genescà et al. 2002; Zhang et al. 2008; Wang et al. 2013). However, there are 
several confounding factors that determine the extent and degree of the damage, 
like the duration of ischemia and the tissue type (Gillani et al. 2012).  In IR 
studies, apoptosis has been shown to exceed necrosis in skeletal muscle (Wang 
et al. 2008), as well as the heart (McCully et al. 2004), liver (Rüdiger & Clavien 
2002), kidney (Du et al. 2003), and brain (Vogt et al. 1998). Kajstura et al 
demonstrated that cardiomyocyte apoptosis began after 2 hours of ischemia in 
vivo (Kajstura et al. 1996). It was estimated that the ratio of apoptotic and 
necrotic cell death is 31:1 at 2 hours after rat coronary artery occlusion (Anversa 
et al. 1998). While in skeletal muscle the difference did not appear to be that 
extensive, it was estimated to be 2:1 after 4 hours of ischemia and 24 hours of 
reperfusion in an in vitro rat study (Wang et al. 2008). 
Apoptosis is a programmed cell death triggered by stimuli from outside or 
within the cell, leading to the activation of caspases and subsequent cell death 
(Primeau et al. 2002). The apoptotic program is complex, involving pro-apoptotic 
and protective proteins. Controlling these factors can modify the outcome of the 
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response to an apoptotic stimulus (Scarabelli et al. 2006). The knowledge that IR 
could induce apoptosis in skeletal muscle is clinically relevant, since it could 
allow for a therapeutic design aimed at apoptosis inhibition. Caspases are the 
executioners of the apoptotic process (Fischer et al. 2003). TNF-α is one of the 
most important external stimuli capable of inducing cell apoptosis in response to 
IR (de Nigris et al. 2003; Haddad 2004; Wu et al. 2014). Mitochondria appear as 
the main source of internal apoptotic stimuli, due to apoptotic factors present in 
the mitochondrial intermembrane space (Saelens et al. 2004).  Cytochrome c, a 
component of the electron transport chain, is generally the earliest and most 
critical initiating factor for mitochondrial-mediated apoptosis when released into 
the cytosol from the inner mitochondrial membrane (Jiang & Wang 2004). 
 While ischaemia itself may be an expected cause, inflammation and 
microvascular dysfunction are also strongly involved in the cellular damage seen 
in IR injury, and, to a great extent, in ACS. ROS in particular are considered the 
main factor responsible for cellular damage caused by both IR and ACS  (Perler 
et al. 1990; Sadasivan et al. 1997; Hancock et al. 2001; Chan 2001; Li & Jackson 
2002; Kearns et al. 2004; Wang et al. 2006; Arató et al. 2008; Kearns et al. 2010; 
Wang et al. 2011b; Gillani et al. 2012) Both ischemia and IR are known to induce 
defects in the electron transport chain, leading to increased production of ROS 
(Kalogeris et al. 2014). While there are several sources of ROS, xanthine 
oxidase enzyme and activated neutrophils are the most common source. ROS 
tend to oxidize biomolecules, such as membrane-bound polyunsaturated fatty 
acids and DNA, damaging their structural or functional roles (Chen et al. 2012). 
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In addition, they also activate cyclooxygenase and lipoxygenase pathways 
(Toyokuni 1999), which, in turn, are responsible for neutrophil activation. 
Furthermore, ROS impair endothelium-dependent vasodilator mechanisms, 
exacerbating the microcirculatory dysfunction. Thus, the destructive effects of 
ROS may lead to either necrosis or apoptosis. The intense inflammatory reaction 
also contributes to tissue death in several ways. While activated leukocytes are 
responsible for tissue injury by the capillary plugging and production of proteolytic 
enzymes, inflammatory mediators play a major additional role.  Necroptosis, 
another type of cell death induced mainly by TNF-α and NF-κB signalling, is a 
form of regulated cell death not mediated by caspases (Sun & Wang 2014). 
Inflammation is known to contribute to this process (de Almagro & Vucic 2015). 
Previously, several experimental therapies targeting ROS have 
demonstrated reduction of ACS-associated cell injury, reflecting the reversible 
nature of cell damage. Kearns et al (2004) successfully diminished the cell injury 
in experimental ACS using vitamin C, while Perler et al (1990) did so by the 
ablation of ROS. In a more recent study, a potent antioxidant, N-acetylcysteine, 
demonstrated significant reduction of cell injury due to ACS (Kearns et al. 2010). 
 
4.2.3  Leukocyte Activation 
 Involvement of leukocytes in the pathophysiology of ACS has been one of 
the earliest observations where the differences between ACS and complete 
ischaemia were clearly highlighted. 
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Leukocytes, predominantly neutrophils, significantly contribute to the 
pathogenesis of IR injury (Korthuis et al. 1988; Carden et al. 1990; Schofield et 
al. 2013; Sabido et al. 1994). Similar role for neutrophils has been demonstrated 
in ACS (Sadasivan et al. 1997; Lawendy et al. 2011; Lawendy et al. 2015). 
Ischaemic insult leads to upregulation of chemical mediators, which, in turn, 
activate neutrophils. TNF-α, IL-1β, IL-6 and IL-8 are all major chemical mediators 
involved in the neutrophil activation process (Ball et al. 2013). Activated 
neutrophils further exacerbate the tissue damage by the release of ROS, 
proteolytic enzymes, and physical blockage of the capillaries thereby preventing 
reperfusion of the tissue (Schofield et al. 2013). 
 Endothelium is very sensitive to any change in the internal milieu of the 
blood vessel. In IR, the endothelium becomes activated and creates a 
proinflammatory and prothrombotic surface to which leukocytes and other blood 
components adhere, resulting in endothelial dysfunction (Girn et al. 2007). 
Integrins and selectins are adhesion molecules that are generated in the 
activation process of endothelium and leukocytes, leading to neutrophil 
recruitment via a multistep cascade.  Activated leukocytes exhibit a characteristic 
sequence pattern within the post capillary venules, namely rolling, adhesion, and 
transendothelial migration (Schofield et al. 2013). 
 Using IVVM, we were able to provide direct evidence of significant 
neutrophil activation in ACS. Both rolling (Figure 3.3) and adherence (Figure 3.4) 
were significantly increased after 2 hours of elevated ICP and 30 minutes of 
reperfusion. These findings are in agreement with previous observations of many 
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other investigators (Sadasivan et al. 1997; Manjoo et al. 2010; Lawendy, 
Sanders, et al. 2011; Lawendy et al. 2014; Lawendy 2014; Lawendy et al. 2015) 
 
4.2.4  TNF-α Levels 
In this study, we observed a marked increase in the levels of circulating 
TNF-α in ACS-challenged animals. TNF-α escalated as ICP increased and 
continued to do so after fasciotomy. This observation had previously been 
reported by Lawendy et al (2014). 
 
 
4.3  THE EFFECT OF EXPERIMENTAL DRUGS ON ACS 
4.3.1  Hydrogen Sulfide 
 Recently, H2S has demonstrated considerable protective role in IR injury. 
The cytoprotective role of H2S has been well documented in different tissues and 
organs. While the mechanism(s) remain largely unknown, it is thought to be 
multifactorial: reduction of the oxidative stress directly, upregulation of antioxidant 
enzymes, promotion of vasorelaxation, and modulation of mitochondrial 
respiration (King & Lefer 2011). H2S has also been shown to attenuate 
leukocyte-mediated inflammation and inhibit apoptosis (Henderson et al. 2011; 
Jackson-Weaver 2012). 
In this study, we examined the potential protective effect of H2S on skeletal 
muscle microcirculation in a rat model of ACS. While H2S has been used 
experimentally as an inhalational gas and as a parenteral preparation via H2S-
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donor molecules, we preferred the parenteral route. We avoided the use of 
gaseous H2S, not only because of its offensive smell and the inherent hazard of 
being a highly toxic gas, but also because of the practical difficulties in 
standardizing the dose, each subject would receive by inhalation. Additionally, 
lung inflammatory reactions have been reported following inhalational H2S 
application (Trevisani et al. 2005), which may have altered our outcomes of the 
inflammatory response due to ACS. Parenteral compounds are safer to store and 
handle, easy to prepare, and permit weight-dependent calculation of 
administered amount, thus ensuring consistency of dosing. Whereas both the 
intraperitoneal and intravenous routes have almost identical pharmacokinetic 
effects (Li et al. 2008), we opted for the intraperitoneal route because of ease of 
administration. 
 Using our rat model of ACS, we were able to demonstrate the 
cytoprotective value of H2S. We found that H2S markedly improved the 
microvascular perfusion (as evidenced by a significant increase in the number of 
continuously perfused capillaries and a reduction in the non-perfused capillaries) 
(Figure 3.1), reduced the overall cell injury (Figure 3.2) and leukocyte activation 
(Figures 3.3. and 3.4) within the post capillary venules. 
 
4.3.1.1 H2S and Microvascular Perfusion 
 Systemic administration of H2S resulted in a noteworthy improvement in 
the muscle perfusion (Figure 3.1). We found a strong inhibitory effect of H2S on 
the no-reflow phenomenon, with substantial increase in the number of 
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continuously perfused capillaries. The net effect of H2S was the re-establishment 
of the microvascular perfusion to levels near those seen in the sham. This 
suggests that GYY4137-derived H2S may have a great potential, not only in 
restoration/maintenance of adequate perfusion, but a subsequent protective role 
against further damage as well. 
 The mechanism(s) by which H2S improved the microcirculation are not 
fully understood, but many pathways could play a role. Perhaps it works through 
re-establishing the redox balance between the pro-oxidants and anti-oxidants by 
directly scavenging ROS, enhancing the innate antioxidant mechanisms, and/or 
reducing the production of ROS themselves (Henderson et al. 2010; Bos et al. 
2014). 
The direct scavenging power of H2S has not escaped a notice by many 
observers. It  has been suggested that H2S is capable of directly scavenging 
superoxide and hydrogen peroxide (Geng et al. 2004), cytotoxic lipid peroxidation 
products (Schreier et al. 2010; Calvert et al. 2010), the highly reactive 
peroxynitrite (Whiteman et al. 2004; Pacher et al. 2007), as well as hypochlorous 
acid (Whiteman et al. 2005; Laggner et al. 2007). The damaging power of ROS is 
due to their extreme reactivity, stemming from their chemical structure: these 
molecules have unpaired electrons. The readiness of H2S to reduce other 
compounds by simply giving away a proton H+ may explain its ability to directly 
reduce ROS, without the need of any enzymatic activity (Nagy et al. 2014). 
H2S appears to play a very important role in augmenting the body’s innate 
antioxidant response (Calvert et al. 2010; Nishida et al. 2012). It has been 
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reported to increase the synthesis of GSH (Jha et al. 2008), and to increase 
activation of SOD (Sun et al. 2012). Both SOD and GSH are well-known 
important defensive mechanisms against the harmful effects of ROS. SOD is the 
major scavenger of superoxide (Fang et al. 2009). H2S has consistently been 
reported to increase the expression of SOD under oxidative stress (Kimura & 
Kimura 2004; Kimura et al. 2006; Wu et al. 2014). On the other hand, GSH is 
known for its potent antioxidant role by reducing hydrogen peroxide to water 
(Albrecht et al. 2011).  
H2S has been shown to reduce oxidative stress by diminishing the 
production of ROS when administered at therapeutic doses (Calvert et al. 2010; 
Chen et al. 2006; Nicholson & Calvert 2010). This effect appears to be mediated 
through inactivating ROS-producing enzymes. Sun et al (2012) observed 
reduction in the levels of ROS through reversible inhibition of mitochondrial 
cytochrome c oxidase through partial inhibition of oxidative phosphorylation. In 
addition, H2S has also been reported to inhibit the expression of NADPH oxidase 
(Tyagi et al. 2009; Muzaffar et al. 2008) and xanthine oxidase, most likely by 
activation of SOD (Bar-Or et al. 2015). 
H2S may have inhibited the no-reflow phenomenon by its potent 
vasodilator effect. It has been proposed that H2S-mediated vasorelaxation is 
mediated through the opening of the mitochondrial KATP channel (Zhao et al. 
2001; Cheng et al. 2004), a property that may be the key factor in reducing the 
infarct size in cardiac muscles following IR injury (Zhao et al. 2001; Johansen et 
al. 2006; Osipov et al. 2009). Interestingly, the vasorelaxing power of H2S 
 
 
86 
appears to be directly correlated to the severity of the local hypoxia (Koenitzer et 
al. 2007; Dombkowski et al. 2011).  
 While NO is considered to be the most potent endothelium-derived 
relaxing factor in the vasculature, H2S is capable of increasing NO levels by 
upregulation of eNOS in ischemic tissue. Conversely, NO has been shown to 
upregulate H2S production by increasing the expression of CSE. Thus, H2S and 
NO appear to be mutually dependent in controlling vascular relaxation (Coletta et 
al. 2012). 
 
4.3.1.2  H2S and Cellular Injury 
We have demonstrated that H2S administration in ACS led to a significant 
reduction in the cellular injury (Figure 3.2). Our findings are consistent with those 
of others, who had demonstrated the cytoprotective potential of H2S in a rat 
model of myocardial IR (Sivarajah et al. 2009; Yao et al. 2012; Wu et al. 2014), 
liver (Mani et al. 2014), and kidney (Lobb et al. 2012) . Henderson et al  had 
shown that not only was H2S protective in skeletal muscle IR, but this protection 
was long lasting, for up to 4 weeks after the initial IR insult (Henderson et al. 
2010). This would suggest that the therapeutic effect of H2S does not merely shift 
the cellular damage several hours ahead, but is truly protective to the tissue. 
While the exact mechanism of cellular protection is most likely related to 
the effect on vasodilation and anti-oxidant properties, there is another possibility: 
inhibition of apoptosis through the direct effect of H2S on mitochondria. H2S has 
been reported to preserve the mitochondrial function and membrane integrity 
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upon administration at the commencement of reperfusion in the ischaemic heart 
(Elrod et al. 2007). Through its ability to inhibit of cytochrome c oxidase function, 
H2S is capable of inhibiting the electron transport chain during early phases of IR, 
thus reducing the overproduction of ROS (Kimura et al. 2005; Wagner et al. 
2009; Veeranki & Tyagi 2014). Mitochondrial protection may also be mediated by 
maintaining membrane potentials. As an active opener of mitochondrial KATP 
channels, H2S would prevent mitochondrial hyperpolarization, calcium overload 
and deleterious opening of the mitochondrial permeability transition pore (Calvert 
et al. 2010; Tang et al. 2013). 
Previously, it has been demonstrated that the administration of H2S at 
reperfusion was capable of reduction of cardiomyocyte apoptosis, both in 
vitro and in vivo (Elrod et al. 2007). This effect is most likely mediated by the 
ability of H2S to inhibit the activation of caspases (Rinaldi et al. 2006). 
H2S could also inhibit apoptosis through inhibition of TNF-α, which is a 
major extracellular stimulus to induce apoptosis. We demonstrated significant 
reduction in the systemic levels of TNF- α, in our experiment, following H2S 
injection (Figure 3.5).  
Given the fact that we administered H2S upon fasciotomy, it would appear 
that the protective effect of H2S was most likely due to its modulation of the 
severity of reperfusion injury that follows fasciotomy. This kind of therapeutic 
application is considered a ‘pharmacological postconditioning’. H2S-mediated 
pharmacological postconditioning had been successfully tested in completely 
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ischaemic rat skeletal muscle, and shown to significantly limit IR-induced 
damage (Henderson et al. 2011). 
 
 
4.3.1.3  H2S and Leukocyte Activation 
 In the current study, H2S demonstrated a strong anti-inflammatory role, 
evidenced by the inhibition of leukocyte activation. H2S administration resulted in 
a significant reduction in the number of both adherent and rolling leukocytes in 
the post-capillary venules (Figures 3.3 and 3.4). This anti-inflammatory property 
of H2S has an added value in the cytoprotective power of H2S, knowing that 
leukocyte activation amplifies the extent of damage through its role in 
inflammatory response. 
 H2S appears to play an important role in inhibiting leukocyte activation in 
normal physiological conditions. For example, inhibition of H2S synthesis in 
healthy animals led to a rapid increase in leukocyte adherence to the vascular 
endothelium (Zanardo et al. 2006). Rats with a diet-induced vitamin B deficiency 
(a co-factor in H2S synthesis) exhibited significantly enhanced accumulation of 
leukocytes in the affected tissues (Flannigan et al. 2014). Heterozygous mice 
deficient in cystathionine-β-synthase (i.e. diminished synthesis of H2S) also 
exhibit increased levels of leukocyte adherence to the vascular endothelium and 
an increase in vascular permeability (Kamath et al. 2006). 
 Just like in our study, administration of a therapeutic dose of H2S has 
been shown to produce a marked suppression of inflammatory response in 
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several other animal models, including that of endotoxic shock (Fiorucci et al. 
2007; Li et al. 2007). While the mechanism of the effect of H2S on leukocyte 
adhesion is yet to be elucidated, Ball et al had demonstrated that H2S 
suppressed leukocytes recruitment due to downregulation of L-selectin 
expression on activated human neutrophils (Ball et al. 2013). Additionally, H2S  
has been shown to inhibit myeloperoxidase activity within neutrophils (Pálinkás et 
al. 2014), promote the shift of macrophages to an anti-inflammatory phenotype 
(Dufton et al. 2012), and induce apoptosis of neutrophils (Serhan et al. 2007). 
Finally, H2S has also been shown to inhibit endothelial ICAM-1 expression, 
triggered by hyperglycaemia (Guan et al. 2013). 
 It has been demonstrated that exogenous administration of H2S is capable 
of reducing the production of a number of proinflammatory cytokines, by 
suppressing NFĸB activity (Sen et al. 2012).  While H2S appears to suppress the 
proinflammatory cytokines, it does not affect the expression of IL-10, which is 
anti-inflammatory (Dinarello 2000; Li et al. 2007). Recently, an interesting 
regulatory interaction between IL-10 and H2S has been described. IL-10-deficient 
mice that spontaneously developed colitis were found to exhibit impaired H2S 
synthesis in the colon. Administration of H2S to these animals  increased IL-10 
expression  and restored normal colonic H2S synthesis (Gemici et al. 2015). 
 H2S also appears to lead to an upregulation of HO, which is known to 
reduce inflammation and exhibit cytoprotection by producing CO and bilirubin 
(Oh et al. 2006; Qingyou et al. 2004; Ryter et al. 2006). 
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4.3.1.3  H2S and TNF-α 
We reported dramatic reduction of TNF-α levels following injection of H2S, 
reaching baseline values in 45 minutes (Figure 3.5). Inhibition of TNF-α (one of 
the most potent pro-inflammatory cytokines) reflects the compelling role of H2S 
as an anti-inflammatory agent, not only protecting tissues locally at the site of 
ischaemia, but also in reducing the systemic sequelae of ACS. 
Interestingly, the TNF-α level pattern was mirrored by leukocyte activation in 
the ACS-challenged muscle, as demonstrated by changes in adherent and rolling 
leukocytes within the post capillary venules (Figures 3.3 and 3.4). 
 
4.3.2  Combination of Hydrogen Sulfide and Carbon Monoxide 
 Both H2S and CO are gaseous signalling molecules with documented 
cytoprotective roles in IR injury (Ryter et al. 2006; Nicholson & Calvert 2010; 
Calvert et al. 2010; Mancardi et al. 2009; Ozaki et al. 2012). Our data 
demonstrated that the improvement in the microvascular perfusion and tissue 
injury, as well as inhibition of leukocyte activation and TNF-α, induced by 
GYY4137-derived H2S, was very comparable to that induced by CORM-3-
derived CO, as reported by Lawendy et al (2014). 
Though we hypothesised that combination of H2S and CO may have an 
added protective benefit in ACS, the combined effect of H2S and CO, in our 
experiments, was not significantly different from that of either of them, to our 
surprise. 
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There could be several possibilities explaining the failure of combination 
treatment. First, perhaps the improvements we had observed could represent the 
maximum improvement that could ever be achieved by any drug. Thus, 
combining two or more agents would not be of value. For example, it is possible 
that capillary damage produced structural no-reflow phenomenon, thus it would 
not respond to any treatment (Galiuto & Crea 2006). 
Another possibility is that both H2S and CO may be exhibiting their 
protective effects by influencing one common pathway, albeit from different 
starting points. For example, H2S may exert some of its anti-inflammatory effects 
through upregulation of HO, while CO is the final product of this pathway (Oh et 
al. 2006; Qingyou et al. 2004; Ryter et al. 2006). HO-derived CO has been 
shown to control vascular tone in NO-dependent manner (Ishikawa et al. 2005); 
H2S has been found to increase NOS expression in endothelial cells (Bir et al. 
2012). The actions of both H2S and CO converge at cGMP, although H2S does 
not directly activate soluble guanylate cyclase (Coletta et al. 2012; Schallner et 
al. 2013). 
 Finally, there is a possibility that a much more complex interplay between 
the two molecules occurs. Some effects may be synergistic, while and others 
antagonistic; the final outcome would be dictated by which effect would be more 
pronounced. For example, CBS has been proposed to be a specific sensor for 
CO (Omura 2005). Thus, CO would have the potential to inhibit CBS activity and, 
therefore, the generation of endogenous H2S (Taoka & Banerjee 2001). 
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4.4  STUDY LIMITATIONS 
While our results demonstrated significant potential role of H2S as a novel 
pharmacological therapeutic agent in ACS, we also recognize that there were 
certain limitations to our study. We used a small animal model of simulated acute 
compartment syndrome, and although there are some similarities between rat 
and human physiology, there are also significant differences between the two 
species (Radermacher & Haouzi 2013). Thus, the observed data may not 
necessarily reflect the human physiologic responses to an extremity ACS. 
In our experiment, we chose to induce ACS for two hours, based on our 
previous publication demonstrating the beneficial effects of CO (Lawendy et al. 
2014). The equivalence of two hours of ACS in rats is questionable when 
compared to humans. Many studies exist that compare the physiological 
processes among living organisms (basal metabolic rate, life span, body mass 
and other parameters), and how they mathematically relate to one another. 
Different equations applicable to all living organisms are available for 
comparative physiology (Marquet et al. 2005; Hulbert et al. 2007; Hoppeler & 
Weibel 2005; Radermacher & Haouzi 2013). Based on these, it was extrapolated 
that one hour of ischaemia in a rat muscle would be the equivalent of about 4 
hours in humans (McGarr 2009; Lawendy 2014), which means that the 2 hours 
we used in the rat model could be equal to 8 hours of ACS in humans. While the 
design of our experiment was not geared to prove this theory, it would be 
interesting to validate it in future studies. 
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Another limitation is the type of tissue examined. Our study was designed 
to determine the potential of H2S in attenuation of the ACS-associated damaging 
effects in the striated muscle. Although our data suggests skeletal muscle 
protection in terms of reduced cell damage, reduced leukocyte activation and 
improved microcirculation, the study design did not address the protective effects 
on the nerves or the antinociceptive effects of H2S. Success in reducing muscle 
damage does not necessarily mean associated nerve protection, as it was 
noticed previously that ischaemic preconditioning may prevent skeletal 
muscle tissue injury, but not nerve lesion upon tourniquet-induced ischaemia 
(Schoen et al. 2007) 
While we demonstrated the immediate protective effects of H2S, we did 
not study the overall long-term changes, sequelae, and recovery of muscle 
function. Thus, any functional clinical outcomes cannot be directly inferred from 
our experiments.  
Finally, while we assessed one dose of H2S delivered intraperitoneally just 
before fasciotomy, we did not investigate the dose–response relationship. 
Knowing that timing of the medication may change the results, additional studies 
would be required to determine the optimum time to administer H2S, and to 
examine the possibility that more than one dose may be needed. 
 
4.5  FUTURE DIRECTIONS 
 In the future, there are several possible experiments that could further 
elucidate the role of hydrogen sulfide in ACS. 
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1. H2S dose-time optimization: Considering that H2S was recently shown to 
serve as a “fuel” for mitochondria during anoxia (Chan & Wallace 2013; Szabo et 
al. 2014), this opens a new horizon for trials during the state of elevated ICP, as 
this mechanism may ameliorate the ischaemic insult itself. Adding to its known 
cytoprotective role, H2S may be able to reduce the demand for fasciotomy. 
2. The next logical step for this line of work is to evaluate functional 
outcomes of the treatment in recovery studies. Gait analysis testing a few days 
following the ACS, and even microscopic examination of skeletal muscle should 
provide the necessary functional as well as pathological data to support the use 
of H2S in clinical trials.  
3.  Evaluation of the effects of H2S on Large animal model would be of more 
clinical relevance than the rat model, and thus would be the next logical step 
forwards clinical trials. 
 
4.6  SUMMARY AND CONCLUSIONS 
Although ACS remains a significant source of morbidity and mortality, 
there has been little progress made toward the development of an adjunctive 
therapeutic intervention, beside surgery, that might ameliorate the damaging 
inflammatory response and associated oxidative stress. The ideal intervention 
would simultaneously target interacting inflammatory mechanisms, abort the 
build up of oedema/increased ICP cycle, and protect the cells from IR injury. 
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We were able to demonstrate that H2S may have a considerable 
cytoprotective role on the skeletal muscle in ACS, acting through several 
possible mechanisms (Figure 4.1). We also established that combining H2S and 
CO was not superior to using either one of the substances individually. Hydrogen 
sulfide shows potential as an adjunctive therapy for compartment syndrome and 
warrants additional assessment to make it a translatable therapy for clinical 
applications. 
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Figure 4.1. Anti-inflammatory actions of H2S. H2S inhibits leukocyte 
adherence to the vascular endothelium, and promotes neutrophil 
apoptosis. Mitochondria can utilize H2S as a fuel in ATP production, 
particularly during anoxia/hypoxia, thus reduce generation of ROS. 
By inhibiting phosphodiesterases (PDE), H2S can elevate tissue 
cGMP levels, which contributes to vasodilation. The antioxidant 
actions of H2S further reduce tissue injury. Several anti-
inflammatory and antioxidant systems are activated by H2S through 
its effects on transcription factors. H2S can stimulate angiogenesis, 
thus promote repair of damaged tissue. 
 Adapted from (Chan & Wallace 2013), with permission. 
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APPENDIX I. Copy of the Animal Protocol Approval 
 
 
 
 
 
 
 
 
 
 
           11.01.13 
      *This is the original approval for this protocol* 
*A full protocol submission will be required in 2017* 
 
Dear Dr. Lawendy: 
 
Your animal use protocol form entitled: 
 
Direct and Remote Organ Injury Following Hind Limb Compartment Syndrome 
 
Funding agency Orthopaedic Trauma Association – Direct and Remote Organ Injury Following Hind Limb 
Compartment Syndrome – Grant #R4889A04 has been approved by the University Council on Animal Care. 
 
This approval is valid from 11.01.13 to 11.30.17 with yearly renewal required. 
 
The protocol number for this project is 2009-083. 
 
1.  This number must be indicated when ordering animals for this project. 
2.  Animals for other projects may not be ordered under this number. 
3.  If no number appears please contact this office when grant approval is received. 
If the application for funding is not successful and you wish to proceed with the project, request that an 
internal scientific peer review be performed by the Animal Use Subcommittee office. 
4.  Purchases of animals other than through this system must be cleared through the ACVS office. Health 
certificates will be required. 
 
ANIMALS APPROVED FOR 4 YEARS 
Species Strain Other Detail Pain 
Level 
Animal # Total 
for 4 years 
Rat Wistar 150-350 g C 680 
Pig Yorkshire-Landrace 50-60 kg B 30 
 
REQUIREMENTS/COMMENTS 
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are 
familiar with the contents of this document. 
 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components 
(biosafety, radiation safety, general laboratory safety) comply with institutional safety standards and have 
received all necessary approvals. Please consult directly with your institutional safety officers. 
 
 
 
 
 
 
 
c.c.  R Bihari, T Carter, K Bothwell, P Coakwell 
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